-
1
-
-
33847047461
-
Epigenetics: a landscape takes shape
-
Goldberg, A. D., Allis, C. D., Bernstein, E. Epigenetics: a landscape takes shape. Cell, 2007, 128: 635-638, doi:10.1016/j.cell.2007.02.006
-
(2007)
Cell
, vol.128
, pp. 635-638
-
-
Goldberg, A.D.1
Allis, C.D.2
Bernstein, E.3
-
2
-
-
84891071460
-
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer
-
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., et al. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem, 2014, 62: 11-33, doi:10.1369/0022155413506582
-
(2014)
J Histochem Cytochem
, vol.62
, pp. 11-33
-
-
Parbin, S.1
Kar, S.2
Shilpi, A.3
Sengupta, D.4
Deb, M.5
Rath, S.K.6
-
3
-
-
79957441575
-
SIRT3 and cancer: tumor promoter or suppressor?
-
Alhazzazi, T. Y., Kamarajan, P., Verdin, E., Kapila, Y. L. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta, 2011, 1816: 80-88, doi:10.1016/j.bbcan.2011.04.004
-
(2011)
Biochim Biophys Acta
, vol.1816
, pp. 80-88
-
-
Alhazzazi, T.Y.1
Kamarajan, P.2
Verdin, E.3
Kapila, Y.L.4
-
4
-
-
79953799195
-
Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer
-
Alhazzazi, T. Y., Kamarajan, P., Joo, N., Huang, J. Y., Verdin, E., D'Silva, N. J., et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer, 2011, 117: 1670-1678, doi:10.1002/cncr.25676
-
(2011)
Cancer
, vol.117
, pp. 1670-1678
-
-
Alhazzazi, T.Y.1
Kamarajan, P.2
Joo, N.3
Huang, J.Y.4
Verdin, E.5
D'Silva, N.J.6
-
5
-
-
47849083984
-
Epigenetic interplay between histone modifications and DNA methylation in gene silencing
-
Vaissiere, T., Sawan, C., Herceg, Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res, 2008, 659: 40-48, doi:10.1016/j.mrrev.2008.02.004
-
(2008)
Mutat Res
, vol.659
, pp. 40-48
-
-
Vaissiere, T.1
Sawan, C.2
Herceg, Z.3
-
6
-
-
0030798245
-
Histone acetylation in chromatin structure and transcription
-
Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature, 1997, 389: 349-352, doi:10.1038/38664
-
(1997)
Nature
, vol.389
, pp. 349-352
-
-
Grunstein, M.1
-
7
-
-
32444434989
-
Histone H4-K16 acetylation controls chromatin structure and protein interactions
-
Shogren-Knaak, M., Ishii, H., Sun, J. M., Pazin, M. J., Davie, J. R., Peterson, C. L. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science, 2006, 311: 844-847, doi:10.1126/science.1124000
-
(2006)
Science
, vol.311
, pp. 844-847
-
-
Shogren-Knaak, M.1
Ishii, H.2
Sun, J.M.3
Pazin, M.J.4
Davie, J.R.5
Peterson, C.L.6
-
8
-
-
68949212379
-
Lysine acetylation targets protein complexes and co-regulates major cellular functions
-
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325: 834-840, doi:10.1126/science.1175371
-
(2009)
Science
, vol.325
, pp. 834-840
-
-
Choudhary, C.1
Kumar, C.2
Gnad, F.3
Nielsen, M.L.4
Rehman, M.5
Walther, T.C.6
-
9
-
-
34547697009
-
Metabolism, cytoskeleton and cellular signalling in the grip of protein Nepsilon - and O-acetylation
-
Yang, X. J., Gregoire, S. Metabolism, cytoskeleton and cellular signalling in the grip of protein Nepsilon - and O-acetylation. EMBO Rep, 2007, 8: 556-562, doi:10.1038/sj.embor.7400977
-
(2007)
EMBO Rep
, vol.8
, pp. 556-562
-
-
Yang, X.J.1
Gregoire, S.2
-
10
-
-
77649101042
-
Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology
-
Joanna, F., van Grunsven, L. A., Mathieu, V., Sarah, S., Sarah, D., Karin, V., et al. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J Cell Mol Med, 2009, 13: 2990-3005, doi:10.1111/j.1582-4934.2009.00831.x
-
(2009)
J Cell Mol Med
, vol.13
, pp. 2990-3005
-
-
Joanna, F.1
van Grunsven, L.A.2
Mathieu, V.3
Sarah, S.4
Sarah, D.5
Karin, V.6
-
11
-
-
0842285672
-
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
-
Chevallier, N., Corcoran, C. M., Lennon, C., Hyjek, E., Chadburn, A., Bardwell, V. J., et al. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood, 2004, 103: 1454-1463, doi:10.1182/blood-2003-06-2081
-
(2004)
Blood
, vol.103
, pp. 1454-1463
-
-
Chevallier, N.1
Corcoran, C.M.2
Lennon, C.3
Hyjek, E.4
Chadburn, A.5
Bardwell, V.J.6
-
12
-
-
17144378591
-
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
-
Huang, B. H., Laban, M., Leung, C. H., Lee, L., Lee, C. K., Salto-Tellez, M., et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ, 2005, 12: 395-404, doi:10.1038/sj.cdd.4401567
-
(2005)
Cell Death Differ
, vol.12
, pp. 395-404
-
-
Huang, B.H.1
Laban, M.2
Leung, C.H.3
Lee, L.4
Lee, C.K.5
Salto-Tellez, M.6
-
13
-
-
21044447215
-
Increased expression of histone deacetylase 2 is found in human gastric cancer
-
Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS, 2005, 113: 264-268, doi:10.1111/j.1600-0463.2005.apm_04.x
-
(2005)
APMIS
, vol.113
, pp. 264-268
-
-
Song, J.1
Noh, J.H.2
Lee, J.H.3
Eun, J.W.4
Ahn, Y.M.5
Kim, S.Y.6
-
14
-
-
0037383786
-
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene
-
Lagger, G., Doetzlhofer, A., Schuettengruber, B., Haidweger, E., Simboeck, E., Tischler, J., et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol, 2003, 23: 2669-2679.
-
(2003)
Mol Cell Biol
, vol.23
, pp. 2669-2679
-
-
Lagger, G.1
Doetzlhofer, A.2
Schuettengruber, B.3
Haidweger, E.4
Simboeck, E.5
Tischler, J.6
-
15
-
-
76749159433
-
The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation
-
Zupkovitz, G., Grausenburger, R., Brunmeir, R., Senese, S., Tischler, J., Jurkin, J., et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol, 2010, 30: 1171-1181, doi:10.1128/MCB.01500-09
-
(2010)
Mol Cell Biol
, vol.30
, pp. 1171-1181
-
-
Zupkovitz, G.1
Grausenburger, R.2
Brunmeir, R.3
Senese, S.4
Tischler, J.5
Jurkin, J.6
-
16
-
-
54349100901
-
HDAC4 promotes growth of colon cancer cells via repression of p21
-
Wilson, A. J., Byun, D. S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell, 2008, 19: 4062-4075, doi:10.1091/mbc.E08-02-0139
-
(2008)
Mol Biol Cell
, vol.19
, pp. 4062-4075
-
-
Wilson, A.J.1
Byun, D.S.2
Nasser, S.3
Murray, L.B.4
Ayyanar, K.5
Arango, D.6
-
17
-
-
58249096131
-
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
-
Mottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene, 2009, 28: 243-256, doi:10.1038/onc.2008.371
-
(2009)
Oncogene
, vol.28
, pp. 243-256
-
-
Mottet, D.1
Pirotte, S.2
Lamour, V.3
Hagedorn, M.4
Javerzat, S.5
Bikfalvi, A.6
-
18
-
-
0035964743
-
Histone deacetylase and DNA methyltransferase in human prostate cancer
-
Patra, S. K., Patra, A., Dahiya, R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun, 2001, 287: 705-713, doi:10.1006/bbrc.2001.5639
-
(2001)
Biochem Biophys Res Commun
, vol.287
, pp. 705-713
-
-
Patra, S.K.1
Patra, A.2
Dahiya, R.3
-
19
-
-
80051614029
-
Molecular marks for epigenetic identification of developmental and cancer stem cells
-
Patra, S. K., Deb, M., Patra, A. Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics, 2011, 2: 27-53, doi:10.1007/s13148-010-0016-0
-
(2011)
Clin Epigenetics
, vol.2
, pp. 27-53
-
-
Patra, S.K.1
Deb, M.2
Patra, A.3
-
20
-
-
1842631408
-
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer
-
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., Robson, C. N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate, 2004, 59: 177-189, doi:10.1002/pros.20022
-
(2004)
Prostate
, vol.59
, pp. 177-189
-
-
Halkidou, K.1
Gaughan, L.2
Cook, S.3
Leung, H.Y.4
Neal, D.E.5
Robson, C.N.6
-
21
-
-
38949086502
-
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
-
Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer, 2008, 98: 604-610, doi:10.1038/sj.bjc.6604199
-
(2008)
Br J Cancer
, vol.98
, pp. 604-610
-
-
Weichert, W.1
Roske, A.2
Gekeler, V.3
Beckers, T.4
Stephan, C.5
Jung, K.6
-
22
-
-
0036500996
-
Colorectal cancer in mice genetically deficient in the mucin Muc2
-
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science, 2002, 295: 1726-1729, doi:10.1126/science.1069094
-
(2002)
Science
, vol.295
, pp. 1726-1729
-
-
Velcich, A.1
Yang, W.2
Heyer, J.3
Fragale, A.4
Nicholas, C.5
Viani, S.6
-
23
-
-
33748482616
-
MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer
-
Yamada, N., Hamada, T., Goto, M., Tsutsumida, H., Higashi, M., Nomoto, M., et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer, 2006, 119: 1850-1857, doi:10.1002/ijc.22047
-
(2006)
Int J Cancer
, vol.119
, pp. 1850-1857
-
-
Yamada, N.1
Hamada, T.2
Goto, M.3
Tsutsumida, H.4
Higashi, M.5
Nomoto, M.6
-
24
-
-
33947658915
-
The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T
-
Hatayama, H., Iwashita, J., Kuwajima, A., Abe, T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem Biophys Res Commun, 2007, 356: 599-603, doi:10.1016/j.bbrc.2007.03.025
-
(2007)
Biochem Biophys Res Commun
, vol.356
, pp. 599-603
-
-
Hatayama, H.1
Iwashita, J.2
Kuwajima, A.3
Abe, T.4
-
25
-
-
66549120804
-
The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection
-
Burger-van Paassen, N., Vincent, A., Puiman, P. J., van der Sluis, M., Bouma, J., Boehm, G., et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J, 2009, 420: 211-219, doi:10.1042/BJ20082222
-
(2009)
Biochem J
, vol.420
, pp. 211-219
-
-
Burger-van Paassen, N.1
Vincent, A.2
Puiman, P.J.3
van der Sluis, M.4
Bouma, J.5
Boehm, G.6
-
26
-
-
77950814683
-
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
-
Schuler, S., Fritsche, P., Diersch, S., Arlt, A., Schmid, R. M., Saur, D., et al. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer, 2010, 9: 80, doi:10.1186/1476-4598-9-80
-
(2010)
Mol Cancer
, vol.9
, pp. 80
-
-
Schuler, S.1
Fritsche, P.2
Diersch, S.3
Arlt, A.4
Schmid, R.M.5
Saur, D.6
-
27
-
-
70349309923
-
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
-
Fritsche, P., Seidler, B., Schuler, S., Schnieke, A., Gottlicher, M., Schmid, R. M., et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut, 2009, 58: 1399-1409, doi:10.1136/gut.2009.180711
-
(2009)
Gut
, vol.58
, pp. 1399-1409
-
-
Fritsche, P.1
Seidler, B.2
Schuler, S.3
Schnieke, A.4
Gottlicher, M.5
Schmid, R.M.6
-
28
-
-
34347339526
-
Role for histone deacetylase 1 in human tumor cell proliferation
-
Senese, S., Zaragoza, K., Minardi, S., Muradore, I., Ronzoni, S., Passafaro, A., et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol, 2007, 27: 4784-4795, doi:10.1128/MCB.00494-07
-
(2007)
Mol Cell Biol
, vol.27
, pp. 4784-4795
-
-
Senese, S.1
Zaragoza, K.2
Minardi, S.3
Muradore, I.4
Ronzoni, S.5
Passafaro, A.6
-
29
-
-
80053161379
-
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
-
Kaminskyy, V. O., Surova, O. V., Vaculova, A., Zhivotovsky, B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis, 2011, 32: 1450-1458, doi:10.1093/carcin/bgr135
-
(2011)
Carcinogenesis
, vol.32
, pp. 1450-1458
-
-
Kaminskyy, V.O.1
Surova, O.V.2
Vaculova, A.3
Zhivotovsky, B.4
-
30
-
-
67349128584
-
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL
-
Aguilera, D. G., Das, C. M., Sinnappah-Kang, N. D., Joyce, C., Taylor, P. H., Wen, S., et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol, 2009, 93: 303-318, doi:10.1007/s11060-008-9788-x
-
(2009)
J Neurooncol
, vol.93
, pp. 303-318
-
-
Aguilera, D.G.1
Das, C.M.2
Sinnappah-Kang, N.D.3
Joyce, C.4
Taylor, P.H.5
Wen, S.6
-
31
-
-
84859565614
-
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
-
Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem, 2012, 113: 2167-2177, doi:10.1002/jcb.24090
-
(2012)
J Cell Biochem
, vol.113
, pp. 2167-2177
-
-
Jung, K.H.1
Noh, J.H.2
Kim, J.K.3
Eun, J.W.4
Bae, H.J.5
Xie, H.J.6
-
32
-
-
33745895281
-
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
-
Butler, L. M., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thaile, M., et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer, 2006, 119: 944-954, doi:10.1002/ijc.21939
-
(2006)
Int J Cancer
, vol.119
, pp. 944-954
-
-
Butler, L.M.1
Liapis, V.2
Bouralexis, S.3
Welldon, K.4
Hay, S.5
Thaile, M.6
-
33
-
-
67649354926
-
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
-
Shankar, S., Davis, R., Singh, K. P., Kurzrock, R., Ross, D. D., Srivastava, R. K. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther, 2009, 8: 1596-1605, doi:10.1158/1535-7163.MCT-08-1004
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1596-1605
-
-
Shankar, S.1
Davis, R.2
Singh, K.P.3
Kurzrock, R.4
Ross, D.D.5
Srivastava, R.K.6
-
34
-
-
84862125485
-
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells
-
Peixoto, P., Castronovo, V., Matheus, N., Polese, C., Peulen, O., Gonzalez, A., et al. HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ, 2012, 19: 1239-1252, doi:10.1038/cdd.2012.3
-
(2012)
Cell Death Differ
, vol.19
, pp. 1239-1252
-
-
Peixoto, P.1
Castronovo, V.2
Matheus, N.3
Polese, C.4
Peulen, O.5
Gonzalez, A.6
-
35
-
-
0037354555
-
Histone acetylation and gastrointestinal carcinogenesis
-
Yasui, W., Oue, N., Ono, S., Mitani, Y., Ito, R., Nakayama, H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci, 2003, 983: 220-231
-
(2003)
Ann N Y Acad Sci
, vol.983
, pp. 220-231
-
-
Yasui, W.1
Oue, N.2
Ono, S.3
Mitani, Y.4
Ito, R.5
Nakayama, H.6
-
36
-
-
80055077899
-
HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia
-
Geng, H., Harvey, C. T., Pittsenbarger, J., Liu, Q., Beer, T. M., Xue, C., et al. HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem, 2011, 286: 38095-38102, doi:10.1074/jbc.M111.257055
-
(2011)
J Biol Chem
, vol.286
, pp. 38095-38102
-
-
Geng, H.1
Harvey, C.T.2
Pittsenbarger, J.3
Liu, Q.4
Beer, T.M.5
Xue, C.6
-
37
-
-
19944399717
-
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia
-
Obach, M., Navarro-Sabate, A., Caro, J., Kong, X., Duran, J., Gomez, M., et al. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J Biol Chem, 2004, 279: 53562-53570, doi:10.1074/jbc.M406096200
-
(2004)
J Biol Chem
, vol.279
, pp. 53562-53570
-
-
Obach, M.1
Navarro-Sabate, A.2
Caro, J.3
Kong, X.4
Duran, J.5
Gomez, M.6
-
38
-
-
0031875003
-
Expression of hypoxia-inducible genes in tumor cells
-
Kress, S., Stein, A., Maurer, P., Weber, B., Reichert, J., Buchmann, A., et al. Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol, 1998, 124: 315-320
-
(1998)
J Cancer Res Clin Oncol
, vol.124
, pp. 315-320
-
-
Kress, S.1
Stein, A.2
Maurer, P.3
Weber, B.4
Reichert, J.5
Buchmann, A.6
-
39
-
-
71749091061
-
The expression and significance of HIF-1alpha and GLUT-3 in glioma
-
Liu, Y., Li, Y. M., Tian, R. F., Liu, W. P., Fei, Z., Long, Q. F., et al. The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res, 2009, 1304: 149-154, doi:10.1016/j.brainres.2009.09.083
-
(2009)
Brain Res
, vol.1304
, pp. 149-154
-
-
Liu, Y.1
Li, Y.M.2
Tian, R.F.3
Liu, W.P.4
Fei, Z.5
Long, Q.F.6
-
40
-
-
58149310725
-
Histone deacetylase inhibitors and genomic instability
-
Eot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., Jaulin, C. Histone deacetylase inhibitors and genomic instability. Cancer Lett, 2009, 274: 169-176, doi:10.1016/j.canlet.2008.06.005
-
(2009)
Cancer Lett
, vol.274
, pp. 169-176
-
-
Eot-Houllier, G.1
Fulcrand, G.2
Magnaghi-Jaulin, L.3
Jaulin, C.4
-
41
-
-
32944468240
-
A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells
-
Kim, I. A., Kim, J. H., Shin, J. H., Kim, I. H., Kim, J. S., Wu, H. G., et al. A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells. Cancer Res Treat, 2005, 37: 122-128, doi:10.4143/crt.2005.37.2.122
-
(2005)
Cancer Res Treat
, vol.37
, pp. 122-128
-
-
Kim, I.A.1
Kim, J.H.2
Shin, J.H.3
Kim, I.H.4
Kim, J.S.5
Wu, H.G.6
-
42
-
-
0242522928
-
Histone deacetylase inhibitors
-
Miller, T. A., Witter, D. J., Belvedere, S. Histone deacetylase inhibitors. J Med Chem, 2003, 46: 5097-5116, doi:10.1021/jm0303094
-
(2003)
J Med Chem
, vol.46
, pp. 5097-5116
-
-
Miller, T.A.1
Witter, D.J.2
Belvedere, S.3
-
43
-
-
67349232749
-
Histone deacetylase inhibitors that target tubulin
-
Schemies, J., Sippl, W., Jung, M. Histone deacetylase inhibitors that target tubulin. Cancer Lett, 2009, 280: 222-232, doi:10.1016/j.canlet.2009.01.040
-
(2009)
Cancer Lett
, vol.280
, pp. 222-232
-
-
Schemies, J.1
Sippl, W.2
Jung, M.3
-
44
-
-
2942564591
-
Sirtuins: Sir2-related NAD-dependent protein deacetylases
-
North, B. J., Verdin, E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol, 2004, 5: 224, doi:10.1186/gb-2004-5-5-224
-
(2004)
Genome Biol
, vol.5
, pp. 224
-
-
North, B.J.1
Verdin, E.2
-
45
-
-
36249016246
-
A therapeutic role for sirtuins in diseases of aging?
-
Westphal, C. H., Dipp, M. A., Guarente, L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci, 2007, 32: 555-560, doi:10.1016/j.tibs.2007.09.008
-
(2007)
Trends Biochem Sci
, vol.32
, pp. 555-560
-
-
Westphal, C.H.1
Dipp, M.A.2
Guarente, L.3
-
46
-
-
39349113616
-
Substituting N(epsilon)-thioacetyl-lysine for N(epsilon)-acetyl-lysine in peptide substrates as a general approach to inhibiting human NAD(+)-dependent protein deacetylases
-
Fatkins, D. G., Zheng, W. Substituting N(epsilon)-thioacetyl-lysine for N(epsilon)-acetyl-lysine in peptide substrates as a general approach to inhibiting human NAD(+)-dependent protein deacetylases. Int J Mol Sci, 2008, 9: 1-11
-
(2008)
Int J Mol Sci
, vol.9
, pp. 1-11
-
-
Fatkins, D.G.1
Zheng, W.2
-
47
-
-
4544318283
-
Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5
-
Biel, M., Kretsovali, A., Karatzali, E., Papamatheakis, J., Giannis, A. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl, 2004, 43: 3974-3976, doi:10.1002/anie.200453879
-
(2004)
Angew Chem Int Ed Engl
, vol.43
, pp. 3974-3976
-
-
Biel, M.1
Kretsovali, A.2
Karatzali, E.3
Papamatheakis, J.4
Giannis, A.5
-
48
-
-
33645221885
-
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage
-
Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S., et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol, 2006, 26: 28-38, doi:10.1128/MCB.26.1.28-38.2006
-
(2006)
Mol Cell Biol
, vol.26
, pp. 28-38
-
-
Solomon, J.M.1
Pasupuleti, R.2
Xu, L.3
McDonagh, T.4
Curtis, R.5
DiStefano, P.S.6
-
49
-
-
0842277812
-
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
-
Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M., Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A, 2004, 101: 1241-1246, doi:10.1073/pnas.0307708100
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 1241-1246
-
-
Gui, C.Y.1
Ngo, L.2
Xu, W.S.3
Richon, V.M.4
Marks, P.A.5
-
50
-
-
65649111534
-
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity
-
Medda, F., Russell, R. J., Higgins, M., McCarthy, A. R., Campbell, J., Slawin, A. M., et al. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem, 2009, 52: 2673-2682, doi:10.1021/jm8014298
-
(2009)
J Med Chem
, vol.52
, pp. 2673-2682
-
-
Medda, F.1
Russell, R.J.2
Higgins, M.3
McCarthy, A.R.4
Campbell, J.5
Slawin, A.M.6
-
51
-
-
0033822112
-
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
-
Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer, 2000, 83: 817-825, doi:10.1054/bjoc.2000.1327
-
(2000)
Br J Cancer
, vol.83
, pp. 817-825
-
-
Sandor, V.1
Senderowicz, A.2
Mertins, S.3
Sackett, D.4
Sausville, E.5
Blagosklonny, M.V.6
-
52
-
-
0034721941
-
Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes
-
Wharton, W., Savell, J., Cress, W. D., Seto, E., Pledger, W. J. Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem, 2000, 275: 33981-33987, doi:10.1074/jbc.M005600200
-
(2000)
J Biol Chem
, vol.275
, pp. 33981-33987
-
-
Wharton, W.1
Savell, J.2
Cress, W.D.3
Seto, E.4
Pledger, W.J.5
-
53
-
-
33748451151
-
Anticancer activities of histone deacetylase inhibitors
-
Bolden, J. E., Peart, M. J., Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 2006, 5: 769-784, doi:10.1038/nrd2133
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 769-784
-
-
Bolden, J.E.1
Peart, M.J.2
Johnstone, R.W.3
-
54
-
-
26444446597
-
Histone modifications as a platform for cancer therapy
-
Espino, P. S., Drobic, B., Dunn, K. L., Davie, J. R. Histone modifications as a platform for cancer therapy. J Cell Biochem, 2005, 94: 1088-1102, doi:10.1002/jcb.20387
-
(2005)
J Cell Biochem
, vol.94
, pp. 1088-1102
-
-
Espino, P.S.1
Drobic, B.2
Dunn, K.L.3
Davie, J.R.4
-
55
-
-
84897838897
-
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells
-
Tu, C. Y., Chen, C. H., Hsia, T. C., Hsu, M. H., Wei, Y. L., Yu, M. C., et al. Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. Biomed Res Int, 2014, 2014: 168949, doi:10.1155/2014/168949
-
(2014)
Biomed Res Int
, vol.2014
, pp. 168949
-
-
Tu, C.Y.1
Chen, C.H.2
Hsia, T.C.3
Hsu, M.H.4
Wei, Y.L.5
Yu, M.C.6
-
56
-
-
12444321545
-
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
-
Kelly, W. K., Richon, V. M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res, 2003, 9: 3578-3588
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3578-3588
-
-
Kelly, W.K.1
Richon, V.M.2
O'Connor, O.3
Curley, T.4
MacGregor-Curtelli, B.5
Tong, W.6
-
57
-
-
21244467166
-
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
-
Bhalla, K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol, 2005, 23: 3971-3993, doi:10.1200/JCO.2005.16.600
-
(2005)
J Clin Oncol
, vol.23
, pp. 3971-3993
-
-
Bhalla, K.N.1
-
58
-
-
26444439216
-
Prospects: histone deacetylase inhibitors
-
Dokmanovic, M., Marks, P. A. Prospects: histone deacetylase inhibitors. J Cell Biochem, 2005, 96: 293-304, doi:10.1002/jcb.20532
-
(2005)
J Cell Biochem
, vol.96
, pp. 293-304
-
-
Dokmanovic, M.1
Marks, P.A.2
-
59
-
-
16544379283
-
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
-
Marchion, D. C., Bicaku, E., Daud, A. I., Richon, V., Sullivan, D. M., Munster, P. N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem, 2004, 92: 223-237, doi:10.1002/jcb.20045
-
(2004)
J Cell Biochem
, vol.92
, pp. 223-237
-
-
Marchion, D.C.1
Bicaku, E.2
Daud, A.I.3
Richon, V.4
Sullivan, D.M.5
Munster, P.N.6
-
60
-
-
33745714230
-
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
-
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res, 2006, 66: 6361-6369, doi:10.1158/0008-5472.CAN-06-0080
-
(2006)
Cancer Res
, vol.66
, pp. 6361-6369
-
-
Gore, S.D.1
Baylin, S.2
Sugar, E.3
Carraway, H.4
Miller, C.B.5
Carducci, M.6
-
61
-
-
31444438952
-
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
-
Maslak, P., Chanel, S., Camacho, L. H., Soignet, S., Pandolfi, P. P., Guernah, I., et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia, 2006, 20: 212-217, doi:10.1038/sj.leu.2404050
-
(2006)
Leukemia
, vol.20
, pp. 212-217
-
-
Maslak, P.1
Chanel, S.2
Camacho, L.H.3
Soignet, S.4
Pandolfi, P.P.5
Guernah, I.6
-
62
-
-
33750530675
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
-
Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108: 3271-3279, doi:10.1182/blood-2006-03-009142
-
(2006)
Blood
, vol.108
, pp. 3271-3279
-
-
Garcia-Manero, G.1
Kantarjian, H.M.2
Sanchez-Gonzalez, B.3
Yang, H.4
Rosner, G.5
Verstovsek, S.6
-
63
-
-
0038284073
-
Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer
-
Nemunaitis, J. J., Orr, D., Eager, R., Cunningham, C. C., Williams, A., Mennel, R., et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J, 2003, 9: 58-66
-
(2003)
Cancer J
, vol.9
, pp. 58-66
-
-
Nemunaitis, J.J.1
Orr, D.2
Eager, R.3
Cunningham, C.C.4
Williams, A.5
Mennel, R.6
-
64
-
-
9444287120
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
-
Undevia, S. D., Kindler, H. L., Janisch, L., Olson, S. C., Schilsky, R. L., Vogelzang, N. J., et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol, 2004, 15: 1705-1711, doi:10.1093/annonc/mdh438
-
(2004)
Ann Oncol
, vol.15
, pp. 1705-1711
-
-
Undevia, S.D.1
Kindler, H.L.2
Janisch, L.3
Olson, S.C.4
Schilsky, R.L.5
Vogelzang, N.J.6
-
65
-
-
0242493856
-
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
-
Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., Grant, S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 2003, 102: 3765-3774, doi:10.1182/blood-2003-03-0737
-
(2003)
Blood
, vol.102
, pp. 3765-3774
-
-
Yu, C.1
Rahmani, M.2
Conrad, D.3
Subler, M.4
Dent, P.5
Grant, S.6
-
66
-
-
33745888156
-
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
-
Fiskus, W., Pranpat, M., Bali, P., Balasis, M., Kumaraswamy, S., Boyapalle, S., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood, 2006, 108: 645-652, doi:10.1182/blood-2005-11-4639
-
(2006)
Blood
, vol.108
, pp. 645-652
-
-
Fiskus, W.1
Pranpat, M.2
Bali, P.3
Balasis, M.4
Kumaraswamy, S.5
Boyapalle, S.6
-
67
-
-
26444561533
-
Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family
-
Chen, Z. X., Mann, J. R., Hsieh, C. L., Riggs, A. D., Chedin, F. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. J Cell Biochem, 2005, 95: 902-917, doi:10.1002/jcb.20447
-
(2005)
J Cell Biochem
, vol.95
, pp. 902-917
-
-
Chen, Z.X.1
Mann, J.R.2
Hsieh, C.L.3
Riggs, A.D.4
Chedin, F.5
-
68
-
-
78651162036
-
Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis
-
Allfrey, V. G., Faulkner, R., Mirsky, A. E. Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci U S A, 1964, 51: 786-794
-
(1964)
Proc Natl Acad Sci U S A
, vol.51
, pp. 786-794
-
-
Allfrey, V.G.1
Faulkner, R.2
Mirsky, A.E.3
-
69
-
-
0028885077
-
Identification of a gene encoding a yeast histone H4 acetyltransferase
-
Kleff, S., Andrulis, E. D., Anderson, C. W., Sternglanz, R. Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem, 1995, 270: 24674-24677
-
(1995)
J Biol Chem
, vol.270
, pp. 24674-24677
-
-
Kleff, S.1
Andrulis, E.D.2
Anderson, C.W.3
Sternglanz, R.4
-
70
-
-
0022365083
-
Deposition-related histone acetylation in micronuclei of conjugating Tetrahymena
-
Allis, C. D., Chicoine, L. G., Richman, R., Schulman, I. G. Deposition-related histone acetylation in micronuclei of conjugating Tetrahymena. Proc Natl Acad Sci U S A, 1985, 82: 8048-8052
-
(1985)
Proc Natl Acad Sci U S A
, vol.82
, pp. 8048-8052
-
-
Allis, C.D.1
Chicoine, L.G.2
Richman, R.3
Schulman, I.G.4
-
71
-
-
0016723918
-
Processing of newly synthesized histone molecules
-
Ruiz-Carrillo, A., Wangh, L. J., Allfrey, V. G. Processing of newly synthesized histone molecules. Science, 1975, 190: 117-128
-
(1975)
Science
, vol.190
, pp. 117-128
-
-
Ruiz-Carrillo, A.1
Wangh, L.J.2
Allfrey, V.G.3
-
72
-
-
0030271392
-
The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism
-
Parthun, M. R., Widom, J., Gottschling, D. E. The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell, 1996, 87: 85-94
-
(1996)
Cell
, vol.87
, pp. 85-94
-
-
Parthun, M.R.1
Widom, J.2
Gottschling, D.E.3
-
73
-
-
84869988557
-
Histone acetyltransferases: Rising ancient counterparts to protein kinases
-
Yuan, H., Marmorstein, R. Histone acetyltransferases: Rising ancient counterparts to protein kinases. Biopolymers, 2013, 99: 98-111, doi:10.1002/bip.22128
-
(2013)
Biopolymers
, vol.99
, pp. 98-111
-
-
Yuan, H.1
Marmorstein, R.2
-
74
-
-
0020403437
-
Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog
-
Cullis, P. M., Wolfenden, R., Cousens, L. S., Alberts, B. M. Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog. J Biol Chem, 1982, 257: 12165-12169
-
(1982)
J Biol Chem
, vol.257
, pp. 12165-12169
-
-
Cullis, P.M.1
Wolfenden, R.2
Cousens, L.S.3
Alberts, B.M.4
-
75
-
-
4043146501
-
Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression
-
Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V., Ravindran, A., Sadhale, P. P., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem, 2004, 279: 33716-33726, doi:10.1074/jbc.M402839200
-
(2004)
J Biol Chem
, vol.279
, pp. 33716-33726
-
-
Balasubramanyam, K.1
Altaf, M.2
Varier, R.A.3
Swaminathan, V.4
Ravindran, A.5
Sadhale, P.P.6
-
76
-
-
10944243759
-
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription
-
Balasubramanyam, K., Varier, R. A., Altaf, M., Swaminathan, V., Siddappa, N. B., Ranga, U., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem, 2004, 279: 51163-51171, doi:10.1074/jbc.M409024200
-
(2004)
J Biol Chem
, vol.279
, pp. 51163-51171
-
-
Balasubramanyam, K.1
Varier, R.A.2
Altaf, M.3
Swaminathan, V.4
Siddappa, N.B.5
Ranga, U.6
-
77
-
-
27644473204
-
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
-
Stimson, L., Rowlands, M. G., Newbatt, Y. M., Smith, N. F., Raynaud, F. I., Rogers, P., et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther, 2005, 4: 1521-1532, doi:10.1158/1535-7163.MCT-05-0135
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 1521-1532
-
-
Stimson, L.1
Rowlands, M.G.2
Newbatt, Y.M.3
Smith, N.F.4
Raynaud, F.I.5
Rogers, P.6
-
78
-
-
34547864553
-
Distinct GCN5/PCAF-containing complex es function as co-activators and are involved in transcription factor and global histone acetylation
-
Nagy, Z., Tora, L. Distinct GCN5/PCAF-containing complex es function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene, 2007, 26: 5341-5357, doi:10.1038/sj.onc.1210604
-
(2007)
Oncogene
, vol.26
, pp. 5341-5357
-
-
Nagy, Z.1
Tora, L.2
-
79
-
-
24944516931
-
A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM
-
Sun, Y., Jiang, X., Chen, S., Fernandes, N., Price, B. D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci U S A, 2005, 102: 13182-13187, doi:10.1073/pnas.0504211102
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 13182-13187
-
-
Sun, Y.1
Jiang, X.2
Chen, S.3
Fernandes, N.4
Price, B.D.5
-
80
-
-
84870375316
-
Histone lysine methylation dynamics: establishment, regulation, and biological impact
-
Black, J. C., Van Rechem, C., Whetstine, J. R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell, 2012, 48: 491-507, doi:10.1016/j.molcel.2012.11.006S1097-2765(12)00937-9 [pii]
-
(2012)
Mol Cell
, vol.48
, pp. 491-507
-
-
Black, J.C.1
Van Rechem, C.2
Whetstine, J.R.3
-
81
-
-
0034632829
-
Regulation of chromatin structure by site-specific histone H3 methyltransferases
-
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature, 2000, 406: 593-599, doi:10.1038/35020506
-
(2000)
Nature
, vol.406
, pp. 593-599
-
-
Rea, S.1
Eisenhaber, F.2
O'Carroll, D.3
Strahl, B.D.4
Sun, Z.W.5
Schmid, M.6
-
82
-
-
33745632390
-
The epigenetic magic of histone lysine methylation
-
Jenuwein, T. The epigenetic magic of histone lysine methylation. FEBS J, 2006, 273: 3121-3135, doi:10.1111/j.1742-4658.2006.05343.x
-
(2006)
FEBS J
, vol.273
, pp. 3121-3135
-
-
Jenuwein, T.1
-
83
-
-
23944509075
-
The SET-domain protein superfamily: protein lysine methyltransferases
-
Dillon, S. C., Zhang, X., Trievel, R. C., Cheng, X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol, 2005, 6: 227, doi:10.1186/gb-2005-6-8-227
-
(2005)
Genome Biol
, vol.6
, pp. 227
-
-
Dillon, S.C.1
Zhang, X.2
Trievel, R.C.3
Cheng, X.4
-
84
-
-
17444375685
-
hDOT1L links histone methylation to leukemogenesis
-
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., et al. hDOT1L links histone methylation to leukemogenesis. Cell, 2005, 121: 167-178, doi:10.1016/j.cell.2005.02.020
-
(2005)
Cell
, vol.121
, pp. 167-178
-
-
Okada, Y.1
Feng, Q.2
Lin, Y.3
Jiang, Q.4
Li, Y.5
Coffield, V.M.6
-
85
-
-
0037077178
-
Dot1p modulates silencing in yeast by methylation of the nucleosome core
-
van Leeuwen, F., Gafken, P. R., Gottschling, D. E. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell, 2002, 109: 745-756
-
(2002)
Cell
, vol.109
, pp. 745-756
-
-
van Leeuwen, F.1
Gafken, P.R.2
Gottschling, D.E.3
-
86
-
-
79959960773
-
The diverse functions of Dot1 and H3K79 methylation
-
Nguyen, A. T., Zhang, Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev, 2011, 25: 1345-1358, doi:10.1101/gad.2057811
-
(2011)
Genes Dev
, vol.25
, pp. 1345-1358
-
-
Nguyen, A.T.1
Zhang, Y.2
-
87
-
-
0242669199
-
Coordinated histone modifications mediated by a CtBP co-repressor complex
-
Shi, Y., Sawada, J., Sui, G., Affarel, B., Whetstine, J. R., Lan, F., et al. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature, 2003, 422: 735-738, doi:10.1038/nature01550
-
(2003)
Nature
, vol.422
, pp. 735-738
-
-
Shi, Y.1
Sawada, J.2
Sui, G.3
Affarel, B.4
Whetstine, J.R.5
Lan, F.6
-
88
-
-
11144332565
-
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
-
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004, 119: 941-953, doi:10.1016/j.cell.2004.12.012
-
(2004)
Cell
, vol.119
, pp. 941-953
-
-
Shi, Y.1
Lan, F.2
Matson, C.3
Mulligan, P.4
Whetstine, J.R.5
Cole, P.A.6
-
89
-
-
33646138230
-
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor
-
Yamane, K., Toumazou, C., Tsukada, Y., Erdjument-Bromage, H., Tempst, P., Wong, J., et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell, 2006, 125: 483-495, doi:10.1016/j.cell.2006.03.027
-
(2006)
Cell
, vol.125
, pp. 483-495
-
-
Yamane, K.1
Toumazou, C.2
Tsukada, Y.3
Erdjument-Bromage, H.4
Tempst, P.5
Wong, J.6
-
90
-
-
32844454603
-
Histone demethylation by a family of JmjC domain-containing proteins
-
Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M. E., Borchers, C. H., Tempst, P., et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature, 2006, 439: 811-816, doi:10.1038/nature04433
-
(2006)
Nature
, vol.439
, pp. 811-816
-
-
Tsukada, Y.1
Fang, J.2
Erdjument-Bromage, H.3
Warren, M.E.4
Borchers, C.H.5
Tempst, P.6
-
91
-
-
33846025127
-
Dynamic regulation of histone lysine methylation by demethylases
-
Shi, Y., Whetstine, J. R. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell, 2007, 25: 1-14, doi:10.1016/j.molcel.2006.12.010
-
(2007)
Mol Cell
, vol.25
, pp. 1-14
-
-
Shi, Y.1
Whetstine, J.R.2
-
92
-
-
33745847680
-
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36
-
Klose, R. J., Yamane, K., Bae, Y., Zhang, D., Erdjument-Bromage, H., Tempst, P., et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature, 2006, 442: 312-316, doi:10.1038/nature04853
-
(2006)
Nature
, vol.442
, pp. 312-316
-
-
Klose, R.J.1
Yamane, K.2
Bae, Y.3
Zhang, D.4
Erdjument-Bromage, H.5
Tempst, P.6
-
93
-
-
33745146571
-
Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells
-
Fodor, B. D., Kubicek, S., Yonezawa, M., O'Sullivan, R. J., Sengupta, R., Perez-Burgos, L., et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev, 2006, 20: 1557-1562, doi:10.1101/gad.388206
-
(2006)
Genes Dev
, vol.20
, pp. 1557-1562
-
-
Fodor, B.D.1
Kubicek, S.2
Yonezawa, M.3
O'Sullivan, R.J.4
Sengupta, R.5
Perez-Burgos, L.6
-
94
-
-
33746332412
-
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
-
Cloos, P. A., Christensen, J., Agger, K., Maiolica, A., Rappsilber, J., Antal, T., et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature, 2006, 442: 307-311, doi:10.1038/nature04837
-
(2006)
Nature
, vol.442
, pp. 307-311
-
-
Cloos, P.A.1
Christensen, J.2
Agger, K.3
Maiolica, A.4
Rappsilber, J.5
Antal, T.6
-
95
-
-
33646124469
-
Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases
-
Whetstine, J. R., Nottke, A., Lan, F., Huarte, M., Smolikov, S., Chen, Z., et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell, 2006, 125: 467-481, doi:10.1016/j.cell.2006.03.028
-
(2006)
Cell
, vol.125
, pp. 467-481
-
-
Whetstine, J.R.1
Nottke, A.2
Lan, F.3
Huarte, M.4
Smolikov, S.5
Chen, Z.6
-
96
-
-
67649800263
-
Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins
-
Trojer, P., Zhang, J., Yonezawa, M., Schmidt, A., Zheng, H., Jenuwein, T., et al. Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins. J Biol Chem, 2009, 284: 8395-8405, doi:10.1074/jbc.M807818200
-
(2009)
J Biol Chem
, vol.284
, pp. 8395-8405
-
-
Trojer, P.1
Zhang, J.2
Yonezawa, M.3
Schmidt, A.4
Zheng, H.5
Jenuwein, T.6
-
97
-
-
33847076849
-
Chromatin modifications and their function
-
Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128: 693-705, doi:10.1016/j.cell.2007.02.005
-
(2007)
Cell
, vol.128
, pp. 693-705
-
-
Kouzarides, T.1
-
98
-
-
34948839944
-
Facultative heterochromatin: is there a distinctive molecular signature?
-
Trojer, P., Reinberg, D. Facultative heterochromatin: is there a distinctive molecular signature? Mol Cell, 2007, 28: 1-13, doi:10.1016/j.molcel.2007.09.011
-
(2007)
Mol Cell
, vol.28
, pp. 1-13
-
-
Trojer, P.1
Reinberg, D.2
-
99
-
-
34848911602
-
Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4
-
Vermeulen, M., Mulder, K. W., Denissov, S., Pijnappel, W. W., van Schaik, F. M., Varier, R. A., et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell, 2007, 131: 58-69, doi:10.1016/j.cell.2007.08.016
-
(2007)
Cell
, vol.131
, pp. 58-69
-
-
Vermeulen, M.1
Mulder, K.W.2
Denissov, S.3
Pijnappel, W.W.4
van Schaik, F.M.5
Varier, R.A.6
-
100
-
-
0035282573
-
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
-
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature, 2001, 410: 116-120, doi:10.1038/35065132
-
(2001)
Nature
, vol.410
, pp. 116-120
-
-
Lachner, M.1
O'Carroll, D.2
Rea, S.3
Mechtler, K.4
Jenuwein, T.5
-
101
-
-
84895925247
-
Context-specific regulation of cancer epigenomes by histone and transcription factor methylation
-
Sarris, M., Nikolaou, K., Talianidis, I. Context-specific regulation of cancer epigenomes by histone and transcription factor methylation. Oncogene, 2014, 33: 1207-1217, doi:10.1038/onc.2013.87onc201387 [pii]
-
(2014)
Oncogene
, vol.33
, pp. 1207-1217
-
-
Sarris, M.1
Nikolaou, K.2
Talianidis, I.3
-
102
-
-
45549087777
-
Direct interaction between SET8 and proliferating cell nuclear antigen couples H4-K20 methylation with DNA replication
-
Huen, M. S., Sy, S. M., van Deursen, J. M., Chen, J. Direct interaction between SET8 and proliferating cell nuclear antigen couples H4-K20 methylation with DNA replication. J Biol Chem, 2008, 283: 11073-11077, doi:10.1074/jbc.C700242200
-
(2008)
J Biol Chem
, vol.283
, pp. 11073-11077
-
-
Huen, M.S.1
Sy, S.M.2
van Deursen, J.M.3
Chen, J.4
-
103
-
-
38049075810
-
The histone methyltransferase SET8 is required for S-phase progression
-
Jorgensen, S., Elvers, I., Trelle, M. B., Menzel, T., Eskildsen, M., Jensen, O. N., et al. The histone methyltransferase SET8 is required for S-phase progression. J Cell Biol, 2007, 179: 1337-1345, doi:10.1083/jcb.200706150
-
(2007)
J Cell Biol
, vol.179
, pp. 1337-1345
-
-
Jorgensen, S.1
Elvers, I.2
Trelle, M.B.3
Menzel, T.4
Eskildsen, M.5
Jensen, O.N.6
-
104
-
-
0036714189
-
Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes
-
Rice, J. C., Nishioka, K., Sarma, K., Steward, R., Reinberg, D., Allis, C. D. Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes. Genes Dev, 2002, 16: 2225-2230, doi:10.1101/gad.1014902
-
(2002)
Genes Dev
, vol.16
, pp. 2225-2230
-
-
Rice, J.C.1
Nishioka, K.2
Sarma, K.3
Steward, R.4
Reinberg, D.5
Allis, C.D.6
-
105
-
-
78651330886
-
SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation
-
Jorgensen, S., Eskildsen, M., Fugger, K., Hansen, L., Larsen, M. S., Kousholt, A. N., et al. SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation. J Cell Biol, 2011, 192: 43-54, doi:10.1083/jcb.201009076
-
(2011)
J Cell Biol
, vol.192
, pp. 43-54
-
-
Jorgensen, S.1
Eskildsen, M.2
Fugger, K.3
Hansen, L.4
Larsen, M.S.5
Kousholt, A.N.6
-
106
-
-
78149281634
-
The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells
-
Tardat, M., Brustel, J., Kirsh, O., Lefevbre, C., Callanan, M., Sardet, C., et al. The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells. Nat Cell Biol, 2010, 12: 1086-1093, doi:10.1038/ncb2113
-
(2010)
Nat Cell Biol
, vol.12
, pp. 1086-1093
-
-
Tardat, M.1
Brustel, J.2
Kirsh, O.3
Lefevbre, C.4
Callanan, M.5
Sardet, C.6
-
107
-
-
84870529834
-
The role of PR-Set7 in replication licensing depends on Suv4-20h
-
Beck, D. B., Burton, A., Oda, H., Ziegler-Birling, C., Torres-Padilla, M. E., Reinberg, D. The role of PR-Set7 in replication licensing depends on Suv4-20h. Genes Dev, 2012, 26: 2580-2589, doi:10.1101/gad.195636.112
-
(2012)
Genes Dev
, vol.26
, pp. 2580-2589
-
-
Beck, D.B.1
Burton, A.2
Oda, H.3
Ziegler-Birling, C.4
Torres-Padilla, M.E.5
Reinberg, D.6
-
108
-
-
33845666681
-
Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair
-
Botuyan, M. V., Lee, J., Ward, I. M., Kim, J. E., Thompson, J. R., Chen, J., et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell, 2006, 127: 1361-1373, doi:10.1016/j.cell.2006.10.043
-
(2006)
Cell
, vol.127
, pp. 1361-1373
-
-
Botuyan, M.V.1
Lee, J.2
Ward, I.M.3
Kim, J.E.4
Thompson, J.R.5
Chen, J.6
-
109
-
-
84904884937
-
EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4
-
Chou, R. H., Wang, Y. N., Hsieh, Y. H., Li, L. Y., Xia, W., Chang, W. C., et al. EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Dev Cell, 2014, 30: 224-237, doi:10.1016/j.devcel.2014.06.008
-
(2014)
Dev Cell
, vol.30
, pp. 224-237
-
-
Chou, R.H.1
Wang, Y.N.2
Hsieh, Y.H.3
Li, L.Y.4
Xia, W.5
Chang, W.C.6
-
110
-
-
2642542643
-
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin
-
Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev, 2004, 18: 1251-1262, doi:10.1101/gad.300704
-
(2004)
Genes Dev
, vol.18
, pp. 1251-1262
-
-
Schotta, G.1
Lachner, M.2
Sarma, K.3
Ebert, A.4
Sengupta, R.5
Reuter, G.6
-
111
-
-
84855340668
-
SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities
-
Yang, F., Sun, L., Li, Q., Han, X., Lei, L., Zhang, H., et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J, 2012, 31: 110-123, doi:10.1038/emboj.2011.364
-
(2012)
EMBO J
, vol.31
, pp. 110-123
-
-
Yang, F.1
Sun, L.2
Li, Q.3
Han, X.4
Lei, L.5
Zhang, H.6
-
112
-
-
0037172665
-
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain
-
Feng, Q., Wang, H., Ng, H. H., Erdjument-Bromage, H., doi:Tempst, P., Struhl, K., et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol, 2002, 12: 1052-1058
-
(2002)
Curr Biol
, vol.12
, pp. 1052-1058
-
-
Feng, Q.1
Wang, H.2
Ng, H.H.3
Erdjument-Bromage, H.4
Tempst, P.5
Struhl, K.6
-
113
-
-
0344837759
-
Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase
-
Min, J., Feng, Q., Li, Z., Zhang, Y., Xu, R. M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell, 2003, 112: 711-723
-
(2003)
Cell
, vol.112
, pp. 711-723
-
-
Min, J.1
Feng, Q.2
Li, Z.3
Zhang, Y.4
Xu, R.M.5
-
114
-
-
0028210328
-
Crystal structure of catechol O-methyltransferase
-
Vidgren, J., Svensson, L. A., Liljas, A. Crystal structure of catechol O-methyltransferase. Nature, 1994, 368: 354-358, doi:10.1038/368354a0
-
(1994)
Nature
, vol.368
, pp. 354-358
-
-
Vidgren, J.1
Svensson, L.A.2
Liljas, A.3
-
115
-
-
77949563562
-
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development
-
Barry, E. R., Corry, G. N., Rasmussen, T. P. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opin Ther Targets, 2010, 14: 405-418, doi:10.1517/14728221003623241
-
(2010)
Expert Opin Ther Targets
, vol.14
, pp. 405-418
-
-
Barry, E.R.1
Corry, G.N.2
Rasmussen, T.P.3
-
116
-
-
82455186371
-
A role for DOT1L in MLL-rearranged leukemias
-
Bernt, K. M., Armstrong, S. A. A role for DOT1L in MLL-rearranged leukemias. Epigenomics, 2011, 3: 667-670, doi:10.2217/epi.11.98
-
(2011)
Epigenomics
, vol.3
, pp. 667-670
-
-
Bernt, K.M.1
Armstrong, S.A.2
-
117
-
-
84878383491
-
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
-
Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood, 2013, 121: 2533-2541, doi:10.1182/blood-2012-11-465120
-
(2013)
Blood
, vol.121
, pp. 2533-2541
-
-
Deshpande, A.J.1
Chen, L.2
Fazio, M.3
Sinha, A.U.4
Bernt, K.M.5
Banka, D.6
-
118
-
-
43249118972
-
Polycomb group genes: keeping stem cell activity in balance
-
Sauvageau, M., Sauvageau, G. Polycomb group genes: keeping stem cell activity in balance. PLoS Biol, 2008, 6: e113, doi:10.1371/journal.pbio.0060113
-
(2008)
PLoS Biol
, vol.6
, pp. e113
-
-
Sauvageau, M.1
Sauvageau, G.2
-
119
-
-
80053139713
-
(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells
-
Choudhury, S. R., Balasubramanian, S., Chew, Y. C., Han, B., Marquez, V. E., Eckert, R. L. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis, 2011, 32: 1525-1532, doi:10.1093/carcin/bgr171
-
(2011)
Carcinogenesis
, vol.32
, pp. 1525-1532
-
-
Choudhury, S.R.1
Balasubramanian, S.2
Chew, Y.C.3
Han, B.4
Marquez, V.E.5
Eckert, R.L.6
-
120
-
-
55949136562
-
Roles of the EZH2 histone methyltransferase in cancer epigenetics
-
Simon, J. A., Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res, 2008, 647: 21-29, doi:10.1016/j.mrfmmm.2008.07.010
-
(2008)
Mutat Res
, vol.647
, pp. 21-29
-
-
Simon, J.A.1
Lange, C.A.2
-
121
-
-
82555173684
-
EZH2 methyltransferase and H3K27 methylation in breast cancer
-
Yoo, K. H., Hennighausen, L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci, 2012, 8: 59-65
-
(2012)
Int J Biol Sci
, vol.8
, pp. 59-65
-
-
Yoo, K.H.1
Hennighausen, L.2
-
122
-
-
73649102464
-
EZH2 is essential for glioblastoma cancer stem cell maintenance
-
Suva, M. L., Riggi, N., Janiszewska, M., Radovanovic, I., Provero, P., Stehle, J. C., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res, 2009, 69: 9211-9218, doi:10.1158/0008-5472.CAN-09-1622
-
(2009)
Cancer Res
, vol.69
, pp. 9211-9218
-
-
Suva, M.L.1
Riggi, N.2
Janiszewska, M.3
Radovanovic, I.4
Provero, P.5
Stehle, J.C.6
-
123
-
-
77957193274
-
Clinical significance of Polycomb gene expression in brain tumors
-
Crea, F., Hurt, E. M., Farrar, W. L. Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer, 2010, 9: 265, doi:10.1186/1476-4598-9-265
-
(2010)
Mol Cancer
, vol.9
, pp. 265
-
-
Crea, F.1
Hurt, E.M.2
Farrar, W.L.3
-
124
-
-
79959416877
-
Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells
-
Orzan, F., Pellegatta, S., Poliani, P. L., Pisati, F., Caldera, V., Menghi, F., et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol, 2011, 37: 381-394, doi:10.1111/j.1365-2990.2010.01132.x
-
(2011)
Neuropathol Appl Neurobiol
, vol.37
, pp. 381-394
-
-
Orzan, F.1
Pellegatta, S.2
Poliani, P.L.3
Pisati, F.4
Caldera, V.5
Menghi, F.6
-
125
-
-
84894093372
-
Altered expression of polycomb group genes in glioblastoma multiforme
-
Li, G., Warden, C., Zou, Z., Neman, J., Krueger, J. S., Jain, A., et al. Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One, 2013, 8: e80970, doi:10.1371/journal.pone.0080970
-
(2013)
PLoS One
, vol.8
, pp. e80970
-
-
Li, G.1
Warden, C.2
Zou, Z.3
Neman, J.4
Krueger, J.S.5
Jain, A.6
-
126
-
-
79957563769
-
The roles of EZH2 in cell lineage commitment
-
Chou, R. H., Yu, Y. L., Hung, M. C. The roles of EZH2 in cell lineage commitment. Am J Transl Res, 2011, 3: 243-250
-
(2011)
Am J Transl Res
, vol.3
, pp. 243-250
-
-
Chou, R.H.1
Yu, Y.L.2
Hung, M.C.3
-
127
-
-
79953211498
-
EZH2 regulates neuronal differentiation of mesenchymal stem cells through PIP5K1C-dependent calcium signaling
-
Yu, Y. L., Chou, R. H., Chen, L. T., Shyu, W. C., Hsieh, S. C., Wu, C. S., et al. EZH2 regulates neuronal differentiation of mesenchymal stem cells through PIP5K1C-dependent calcium signaling. J Biol Chem, 2011, 286: 9657-9667, doi:10.1074/jbc.M110.185124
-
(2011)
J Biol Chem
, vol.286
, pp. 9657-9667
-
-
Yu, Y.L.1
Chou, R.H.2
Chen, L.T.3
Shyu, W.C.4
Hsieh, S.C.5
Wu, C.S.6
-
128
-
-
84875811405
-
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke
-
Yu, Y. L., Chou, R. H., Shyu, W. C., Hsieh, S. C., Wu, C. S., Chiang, S. Y., et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med, 2013, 5: 531-547, doi:10.1002/emmm.201201783
-
(2013)
EMBO Mol Med
, vol.5
, pp. 531-547
-
-
Yu, Y.L.1
Chou, R.H.2
Shyu, W.C.3
Hsieh, S.C.4
Wu, C.S.5
Chiang, S.Y.6
-
129
-
-
84927168923
-
The potential roles of EZH2 in regenerative medicine
-
Chou, R. H., Chiu, L., Yu, Y. L., Shyu, W. C. The potential roles of EZH2 in regenerative medicine. Cell Transplant, 2015, 24: 313-317, doi:10.3727/096368915X686823
-
(2015)
Cell Transplant
, vol.24
, pp. 313-317
-
-
Chou, R.H.1
Chiu, L.2
Yu, Y.L.3
Shyu, W.C.4
-
130
-
-
77953444201
-
High expression of EZH2 is associated with tumor aggres siveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
-
He, L. R., Liu, M. Z., Li, B. K., Jia, W. H., Zhang, Y., Liao, Y. J., et al. High expression of EZH2 is associated with tumor aggres siveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer, 2010, 127: 138-147, doi:10.1002/ijc.25031
-
(2010)
Int J Cancer
, vol.127
, pp. 138-147
-
-
He, L.R.1
Liu, M.Z.2
Li, B.K.3
Jia, W.H.4
Zhang, Y.5
Liao, Y.J.6
-
131
-
-
78049307003
-
Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
-
Hu, S., Yu, L., Li, Z., Shen, Y., Wang, J., Cai, J., et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther, 2010, 10: 788-795
-
(2010)
Cancer Biol Ther
, vol.10
, pp. 788-795
-
-
Hu, S.1
Yu, L.2
Li, Z.3
Shen, Y.4
Wang, J.5
Cai, J.6
-
132
-
-
79951825513
-
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2
-
Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther, 2011, 10: 325-335, doi:10.1158/1535-7163.MCT-10-0788
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 325-335
-
-
Rizzo, S.1
Hersey, J.M.2
Mellor, P.3
Dai, W.4
Santos-Silva, A.5
Liber, D.6
-
133
-
-
78651454089
-
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling
-
Chang, C. J., Yang, J. Y., Xia, W., Chen, C. T., Xie, X., Chao, C. H., et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell, 2011, 19: 86-100, doi:S1535-6108(10)00437-X [pii]10.1016/j.ccr.2010.10.035
-
(2011)
Cancer Cell
, vol.19
, pp. 86-100
-
-
Chang, C.J.1
Yang, J.Y.2
Xia, W.3
Chen, C.T.4
Xie, X.5
Chao, C.H.6
-
134
-
-
84863343713
-
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM
-
Kong, D., Heath, E., Chen, W., Cher, M. L., Powell, I., Heilbrun, L., et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One, 2012, 7: e33729, doi:10.1371/journal.pone.0033729
-
(2012)
PLoS One
, vol.7
, pp. e33729
-
-
Kong, D.1
Heath, E.2
Chen, W.3
Cher, M.L.4
Powell, I.5
Heilbrun, L.6
-
135
-
-
78650987804
-
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
-
Reijm, E. A., Jansen, M. P., Ruigrok-Ritstier, K., van Staveren, I. L., Look, M. P., van Gelder, M. E., et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat, 2011, 125: 387-394, doi:10.1007/s10549-010-0836-9
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 387-394
-
-
Reijm, E.A.1
Jansen, M.P.2
Ruigrok-Ritstier, K.3
van Staveren, I.L.4
Look, M.P.5
van Gelder, M.E.6
-
136
-
-
84863722942
-
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
-
Jansen, M. P., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodriguez-Gonzalez, F. G., et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat, 2012, 133: 937-947, doi:10.1007/s10549-011-1877-4
-
(2012)
Breast Cancer Res Treat
, vol.133
, pp. 937-947
-
-
Jansen, M.P.1
Reijm, E.A.2
Sieuwerts, A.M.3
Ruigrok-Ritstier, K.4
Look, M.P.5
Rodriguez-Gonzalez, F.G.6
-
137
-
-
84876789029
-
Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu
-
Zhang, Y., Liu, G., Lin, C., Liao, G., Tang, B. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci, 2013, 92: 896-902, doi:10.1016/j.lfs.2013.03.010
-
(2013)
Life Sci
, vol.92
, pp. 896-902
-
-
Zhang, Y.1
Liu, G.2
Lin, C.3
Liao, G.4
Tang, B.5
-
138
-
-
84872782925
-
RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy
-
Tang, B., Zhang, Y., Liang, R., Gao, Z., Sun, D., Wang, L. RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncol Rep, 2013, 29: 1037-1042, doi:10.3892/or.2013.2222
-
(2013)
Oncol Rep
, vol.29
, pp. 1037-1042
-
-
Tang, B.1
Zhang, Y.2
Liang, R.3
Gao, Z.4
Sun, D.5
Wang, L.6
-
139
-
-
79960058024
-
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
-
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell, 2011, 20: 53-65, doi:10.1016/j.ccr.2011.06.009
-
(2011)
Cancer Cell
, vol.20
, pp. 53-65
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
Majer, C.R.4
Sneeringer, C.J.5
Song, J.6
-
140
-
-
84876143288
-
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l
-
Chen, L., Deshpande, A. J., Banka, D., Bernt, K. M., Dias, S., Buske, C., et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia, 2013, 27: 813-822, doi:10.1038/leu.2012.327
-
(2013)
Leukemia
, vol.27
, pp. 813-822
-
-
Chen, L.1
Deshpande, A.J.2
Banka, D.3
Bernt, K.M.4
Dias, S.5
Buske, C.6
-
141
-
-
84921370808
-
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L
-
Gibbons, G. S., Owens, S. R., Fearon, E. R., Nikolovska-Coleska, Z. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L. ACS Chem Biol, 2015, 10: 109-114, doi:10.1021/cb500668u
-
(2015)
ACS Chem Biol
, vol.10
, pp. 109-114
-
-
Gibbons, G.S.1
Owens, S.R.2
Fearon, E.R.3
Nikolovska-Coleska, Z.4
-
142
-
-
84886864184
-
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
-
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood, 2013, 122: 1017-1025, doi:10.1182/blood-2013-04-497644
-
(2013)
Blood
, vol.122
, pp. 1017-1025
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
Basavapathruni, A.4
Jin, L.5
Boriack-Sjodin, P.A.6
-
143
-
-
84899459437
-
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor
-
Basavapathruni, A., Olhava, E. J., Daigle, S. R., Therkelsen, C. A., Jin, L., Boriack-Sjodin, P. A., et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos, 2014, 35: 237-252, doi:10.1002/bdd.1889
-
(2014)
Biopharm Drug Dispos
, vol.35
, pp. 237-252
-
-
Basavapathruni, A.1
Olhava, E.J.2
Daigle, S.R.3
Therkelsen, C.A.4
Jin, L.5
Boriack-Sjodin, P.A.6
-
144
-
-
84929100337
-
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
-
Kuhn, M. W., Hadler, M. J., Daigle, S. R., Koche, R. P., Krivtsov, A. V., Olhava, E. J., et al. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 2015, 100: e190-193, doi:10.3324/haematol.2014.115337
-
(2015)
Haematologica
, vol.100
, pp. e190-193
-
-
Kuhn, M.W.1
Hadler, M.J.2
Daigle, S.R.3
Koche, R.P.4
Krivtsov, A.V.5
Olhava, E.J.6
-
145
-
-
84907291965
-
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells
-
Klaus, C. R., Iwanowicz, D., Johnston, D., Campbell, C. A., Smith, J. J., Moyer, M. P., et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther, 2014, 350: 646-656, doi:10.1124/jpet.114.214577
-
(2014)
J Pharmacol Exp Ther
, vol.350
, pp. 646-656
-
-
Klaus, C.R.1
Iwanowicz, D.2
Johnston, D.3
Campbell, C.A.4
Smith, J.J.5
Moyer, M.P.6
-
146
-
-
84870573126
-
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
-
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492: 108-112, doi:10.1038/nature11606
-
(2012)
Nature
, vol.492
, pp. 108-112
-
-
McCabe, M.T.1
Ott, H.M.2
Ganji, G.3
Korenchuk, S.4
Thompson, C.5
Van Aller, G.S.6
-
147
-
-
84871841675
-
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
-
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A, 2012, 109: 21360-21365, doi:10.1073/pnas.1210371110
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 21360-21365
-
-
Qi, W.1
Chan, H.2
Teng, L.3
Li, L.4
Chuai, S.5
Zhang, R.6
-
148
-
-
84879750981
-
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1
-
Konze, K. D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., Macnevin, C. J., et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol, 2013, 8: 1324-1334, doi:10.1021/cb400133j
-
(2013)
ACS Chem Biol
, vol.8
, pp. 1324-1334
-
-
Konze, K.D.1
Ma, A.2
Li, F.3
Barsyte-Lovejoy, D.4
Parton, T.5
Macnevin, C.J.6
-
149
-
-
84921318899
-
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma
-
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K. C., Xiao, Y., et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther, 2014, 13: 842-854, doi:10.1158/1535-7163.MCT-13-0773
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 842-854
-
-
Knutson, S.K.1
Kawano, S.2
Minoshima, Y.3
Warholic, N.M.4
Huang, K.C.5
Xiao, Y.6
-
150
-
-
84911462255
-
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation
-
Bradley, W. D., Arora, S., Busby, J., Balasubramanian, S., Gehling, V. S., Nasveschuk, C. G., et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol, 2014, 21: 1463-1475, doi:10.1016/j.chembiol.2014.09.017
-
(2014)
Chem Biol
, vol.21
, pp. 1463-1475
-
-
Bradley, W.D.1
Arora, S.2
Busby, J.3
Balasubramanian, S.4
Gehling, V.S.5
Nasveschuk, C.G.6
-
151
-
-
78650062951
-
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
-
Velichutina, I., Shaknovich, R., Geng, H., Johnson, N. A., Gascoyne, R. D., Melnick, A. M., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood, 2010, 116: 5247-5255, doi:10.1182/blood-2010-04-280149
-
(2010)
Blood
, vol.116
, pp. 5247-5255
-
-
Velichutina, I.1
Shaknovich, R.2
Geng, H.3
Johnson, N.A.4
Gascoyne, R.D.5
Melnick, A.M.6
-
152
-
-
84877815031
-
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
-
Beguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell, 2013, 23: 677-692, doi:10.1016/j.ccr.2013.04.011
-
(2013)
Cancer Cell
, vol.23
, pp. 677-692
-
-
Beguelin, W.1
Popovic, R.2
Teater, M.3
Jiang, Y.4
Bunting, K.L.5
Rosen, M.6
-
153
-
-
84877324084
-
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
-
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A, 2013, 110: 7922-7927, doi:10.1073/pnas.1303800110
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 7922-7927
-
-
Knutson, S.K.1
Warholic, N.M.2
Wigle, T.J.3
Klaus, C.R.4
Allain, C.J.5
Raimondi, A.6
-
154
-
-
84940093455
-
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia
-
Pappano, W. N., Guo, J., He, Y., Ferguson, D., Jagadeeswaran, S., Osterling, D. J., et al. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. PLoS One, 2015, 10: e0131716, doi:10.1371/journal.pone.0131716
-
(2015)
PLoS One
, vol.10
, pp. e0131716
-
-
Pappano, W.N.1
Guo, J.2
He, Y.3
Ferguson, D.4
Jagadeeswaran, S.5
Osterling, D.J.6
-
155
-
-
84890834128
-
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production
-
Kim, Y., Kim, Y. S., Kim, D. E., Lee, J. S., Song, J. H., Kim, H. G., et al. BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production. Autophagy, 2013, 9: 2126-2139, doi:10.4161/auto.26308
-
(2013)
Autophagy
, vol.9
, pp. 2126-2139
-
-
Kim, Y.1
Kim, Y.S.2
Kim, D.E.3
Lee, J.S.4
Song, J.H.5
Kim, H.G.6
-
156
-
-
84902087529
-
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation
-
Savickiene, J., Treigyte, G., Stirblyte, I., Valiuliene, G., Navakauskiene, R. Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation. Leuk Res, 2014, 38: 822-829, doi:10.1016/j.leukres.2014.04.003
-
(2014)
Leuk Res
, vol.38
, pp. 822-829
-
-
Savickiene, J.1
Treigyte, G.2
Stirblyte, I.3
Valiuliene, G.4
Navakauskiene, R.5
-
157
-
-
84924060693
-
EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells
-
Cui, J., Sun, W., Hao, X., Wei, M., Su, X., Zhang, Y., et al. EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells. Cancer Cell Int, 2015, 15: 4, doi:10.1186/s12935-014-0149-x
-
(2015)
Cancer Cell Int
, vol.15
, pp. 4
-
-
Cui, J.1
Sun, W.2
Hao, X.3
Wei, M.4
Su, X.5
Zhang, Y.6
-
158
-
-
80052473151
-
Structural basis of substrate methylation and inhibition of SMYD2
-
Ferguson, A. D., Larsen, N. A., Howard, T., Pollard, H., Green, I., Grande, C., et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure, 2011, 19: 1262-1273, doi:10.1016/j.str.2011.06.011
-
(2011)
Structure
, vol.19
, pp. 1262-1273
-
-
Ferguson, A.D.1
Larsen, N.A.2
Howard, T.3
Pollard, H.4
Green, I.5
Grande, C.6
-
159
-
-
84930225536
-
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
-
Nguyen, H., Allali-Hassani, A., Antonysamy, S., Chang, S., Chen, L. H., Curtis, C., et al. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem, 2015, 290: 13641-13653, doi:10.1074/jbc.M114.626861
-
(2015)
J Biol Chem
, vol.290
, pp. 13641-13653
-
-
Nguyen, H.1
Allali-Hassani, A.2
Antonysamy, S.3
Chang, S.4
Chen, L.H.5
Curtis, C.6
-
160
-
-
34147173308
-
trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1
-
Schmidt, D. M., McCafferty, D. G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry, 2007, 46: 4408-4416, doi:10.1021/bi0618621
-
(2007)
Biochemistry
, vol.46
, pp. 4408-4416
-
-
Schmidt, D.M.1
McCafferty, D.G.2
-
161
-
-
72249117352
-
Identification of cell-active lysine specific demethylase 1-selective inhibitors
-
Ueda, R., Suzuki, T., Mino, K., Tsumoto, H., Nakagawa, H., Hasegawa, M., et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc, 2009, 131: 17536-17537, doi:10.1021/ja907055q
-
(2009)
J Am Chem Soc
, vol.131
, pp. 17536-17537
-
-
Ueda, R.1
Suzuki, T.2
Mino, K.3
Tsumoto, H.4
Nakagawa, H.5
Hasegawa, M.6
-
162
-
-
77955025931
-
Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1
-
Mimasu, S., Umezawa, N., Sato, S., Higuchi, T., Umehara, T., Yokoyama, S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry, 2010, 49: 6494-6503, doi:10.1021/bi100299r
-
(2010)
Biochemistry
, vol.49
, pp. 6494-6503
-
-
Mimasu, S.1
Umezawa, N.2
Sato, S.3
Higuchi, T.4
Umehara, T.5
Yokoyama, S.6
-
163
-
-
79958247128
-
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors
-
Benelkebir, H., Hodgkinson, C., Duriez, P. J., Hayden, A. L., Bulleid, R. A., Crabb, S. J., et al. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorg Med Chem, 2011, 19: 3709-3716, doi:10.1016/j.bmc.2011.02.017
-
(2011)
Bioorg Med Chem
, vol.19
, pp. 3709-3716
-
-
Benelkebir, H.1
Hodgkinson, C.2
Duriez, P.J.3
Hayden, A.L.4
Bulleid, R.A.5
Crabb, S.J.6
-
164
-
-
84859837026
-
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
-
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell, 2012, 21: 473-487, doi:10.1016/j.ccr.2012.03.014
-
(2012)
Cancer Cell
, vol.21
, pp. 473-487
-
-
Harris, W.J.1
Huang, X.2
Lynch, J.T.3
Spencer, G.J.4
Hitchin, J.R.5
Li, Y.6
-
165
-
-
84933501651
-
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease
-
Maes, T., Mascaro, C., Ortega, A., Lunardi, S., Ciceri, F., Somervaille, T. C., et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics, 2015, 7: 609-626, doi:10.2217/epi.15.9
-
(2015)
Epigenomics
, vol.7
, pp. 609-626
-
-
Maes, T.1
Mascaro, C.2
Ortega, A.3
Lunardi, S.4
Ciceri, F.5
Somervaille, T.C.6
-
166
-
-
84937429405
-
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
-
Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell, 2015, 28: 57-69, doi:10.1016/j.ccell.2015.06.002
-
(2015)
Cancer Cell
, vol.28
, pp. 57-69
-
-
Mohammad, H.P.1
Smitheman, K.N.2
Kamat, C.D.3
Soong, D.4
Federowicz, K.E.5
Van Aller, G.S.6
-
167
-
-
84890448100
-
High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors
-
Sorna, V., Theisen, E. R., Stephens, B., Warner, S. L., Bearss, D. J., Vankayalapati, H., et al. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chem, 2013, 56: 9496-9508, doi:10.1021/jm400870h
-
(2013)
J Med Chem
, vol.56
, pp. 9496-9508
-
-
Sorna, V.1
Theisen, E.R.2
Stephens, B.3
Warner, S.L.4
Bearss, D.J.5
Vankayalapati, H.6
-
168
-
-
84912072883
-
Development and classes of epigenetic drugs for cancer
-
Dhanak, D., Jackson, P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun, 2014, 455: 58-69, doi:10.1016/j.bbrc.2014.07.006
-
(2014)
Biochem Biophys Res Commun
, vol.455
, pp. 58-69
-
-
Dhanak, D.1
Jackson, P.2
-
169
-
-
84922288173
-
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
-
Fiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G., Liu, K., et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 2014, 28: 2155-2164, doi:10.1038/leu.2014.119
-
(2014)
Leukemia
, vol.28
, pp. 2155-2164
-
-
Fiskus, W.1
Sharma, S.2
Shah, B.3
Portier, B.P.4
Devaraj, S.G.5
Liu, K.6
-
170
-
-
84866327150
-
Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1
-
Hazeldine, S., Pachaiyappan, B., Steinbergs, N., Nowotarski, S., Hanson, A. S., Casero, R. A., Jr., et al. Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1. J Med Chem, 2012, 55: 7378-7391, doi:10.1021/jm3002845
-
(2012)
J Med Chem
, vol.55
, pp. 7378-7391
-
-
Hazeldine, S.1
Pachaiyappan, B.2
Steinbergs, N.3
Nowotarski, S.4
Hanson, A.S.5
Casero, R.A.6
-
171
-
-
56749151276
-
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases
-
Rose, N. R., Ng, S. S., Mecinovic, J., Lienard, B. M., Bello, S. H., Sun, Z., et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem, 2008, 51: 7053-7056, doi:10.1021/jm800936s
-
(2008)
J Med Chem
, vol.51
, pp. 7053-7056
-
-
Rose, N.R.1
Ng, S.S.2
Mecinovic, J.3
Lienard, B.M.4
Bello, S.H.5
Sun, Z.6
-
172
-
-
84865120905
-
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
-
Kruidenier, L., Chung, C. W., Cheng, Z., Liddle, J., Che, K., Joberty, G., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature, 2012, 488: 404-408, doi:10.1038/nature11262
-
(2012)
Nature
, vol.488
, pp. 404-408
-
-
Kruidenier, L.1
Chung, C.W.2
Cheng, Z.3
Liddle, J.4
Che, K.5
Joberty, G.6
-
173
-
-
84907526739
-
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
-
Ntziachristos, P., Tsirigos, A., Welstead, G. G., Trimarchi, T., Bakogianni, S., Xu, L., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature, 2014, 514: 513-517, doi:10.1038/nature13605
-
(2014)
Nature
, vol.514
, pp. 513-517
-
-
Ntziachristos, P.1
Tsirigos, A.2
Welstead, G.G.3
Trimarchi, T.4
Bakogianni, S.5
Xu, L.6
-
174
-
-
21044450362
-
MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2
-
Dyson, M. H., Thomson, S., Inagaki, M., Goto, H., Arthur, S. J., Nightingale, K., et al. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci, 2005, 118: 2247-2259, doi:10.1242/jcs.02373
-
(2005)
J Cell Sci
, vol.118
, pp. 2247-2259
-
-
Dyson, M.H.1
Thomson, S.2
Inagaki, M.3
Goto, H.4
Arthur, S.J.5
Nightingale, K.6
-
175
-
-
21344450516
-
Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation
-
Choi, H. S., Choi, B. Y., Cho, Y. Y., Mizuno, H., Kang, B. S., Bode, A. M., et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res, 2005, 65: 5818-5827, doi:10.1158/0008-5472.CAN-05-0197
-
(2005)
Cancer Res
, vol.65
, pp. 5818-5827
-
-
Choi, H.S.1
Choi, B.Y.2
Cho, Y.Y.3
Mizuno, H.4
Kang, B.S.5
Bode, A.M.6
-
176
-
-
33744969113
-
The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation
-
Dong, Z., Bode, A. M. The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation. Mol Carcinog, 2006, 45: 416-421, doi:10.1002/mc.20220
-
(2006)
Mol Carcinog
, vol.45
, pp. 416-421
-
-
Dong, Z.1
Bode, A.M.2
-
177
-
-
58149280831
-
Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells
-
Espino, P. S., Pritchard, S., Heng, H. H., Davie, J. R. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. Int J Cancer, 2009, 124: 562-567, doi:10.1002/ijc.23959
-
(2009)
Int J Cancer
, vol.124
, pp. 562-567
-
-
Espino, P.S.1
Pritchard, S.2
Heng, H.H.3
Davie, J.R.4
-
178
-
-
84888151835
-
R loops are linked to histone H3 S10 phosphorylation and chromatin condensation
-
Castellano-Pozo, M., Santos-Pereira, J. M., Rondon, A. G., Barroso, S., Andujar, E., Perez-Alegre, M., et al. R loops are linked to histone H3 S10 phosphorylation and chromatin condensation. Mol Cell, 2013, 52: 583-590, doi:10.1016/j.molcel.2013.10.006
-
(2013)
Mol Cell
, vol.52
, pp. 583-590
-
-
Castellano-Pozo, M.1
Santos-Pereira, J.M.2
Rondon, A.G.3
Barroso, S.4
Andujar, E.5
Perez-Alegre, M.6
-
179
-
-
84888195489
-
Histone 3 s10 phosphorylation: «caught in the R loop!»
-
Skourti-Stathaki, K., Proudfoot, N. J. Histone 3 s10 phosphorylation: «caught in the R loop!». Mol Cell, 2013, 52: 470-472, doi:10.1016/j.molcel.2013.11.006
-
(2013)
Mol Cell
, vol.52
, pp. 470-472
-
-
Skourti-Stathaki, K.1
Proudfoot, N.J.2
-
180
-
-
2342506598
-
TAF1 activates transcription by phosphorylation of serine 33 in histone H2B
-
Maile, T., Kwoczynski, S., Katzenberger, R. J., Wassarman, D. A., Sauer, F. TAF1 activates transcription by phosphorylation of serine 33 in histone H2B. Science, 2004, 304: 1010-1014, doi:10.1126/science.1095001
-
(2004)
Science
, vol.304
, pp. 1010-1014
-
-
Maile, T.1
Kwoczynski, S.2
Katzenberger, R.J.3
Wassarman, D.A.4
Sauer, F.5
-
181
-
-
37749026136
-
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation
-
Metzger, E., Yin, N., Wissmann, M., Kunowska, N., Fischer, K., Friedrichs, N., et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol, 2008, 10: 53-60, doi:10.1038/ncb1668
-
(2008)
Nat Cell Biol
, vol.10
, pp. 53-60
-
-
Metzger, E.1
Yin, N.2
Wissmann, M.3
Kunowska, N.4
Fischer, K.5
Friedrichs, N.6
-
182
-
-
58149242430
-
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity
-
Xiao, A., Li, H., Shechter, D., Ahn, S. H., Fabrizio, L. A., Erdjument-Bromage, H., et al. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature, 2009, 457: 57-62, doi:nature07668 [pii] 10.1038/nature07668
-
(2009)
Nature
, vol.457
, pp. 57-62
-
-
Xiao, A.1
Li, H.2
Shechter, D.3
Ahn, S.H.4
Fabrizio, L.A.5
Erdjument-Bromage, H.6
-
183
-
-
68249094946
-
Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis
-
Singh, R. K., Kabbaj, M. H., Paik, J., Gunjan, A. Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis. Nat Cell Biol, 2009, 11: 925-933, doi:ncb1903 [pii] 10.1038/ncb1903
-
(2009)
Nat Cell Biol
, vol.11
, pp. 925-933
-
-
Singh, R.K.1
Kabbaj, M.H.2
Paik, J.3
Gunjan, A.4
-
184
-
-
70349975711
-
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin
-
Dawson, M. A., Bannister, A. J., Gottgens, B., Foster, S. D., Bartke, T., Green, A. R., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 2009, 461: 819-822, doi:nature08448 [pii] 10.1038/nature08448
-
(2009)
Nature
, vol.461
, pp. 819-822
-
-
Dawson, M.A.1
Bannister, A.J.2
Gottgens, B.3
Foster, S.D.4
Bartke, T.5
Green, A.R.6
-
185
-
-
84866112974
-
H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes
-
Mahajan, K., Fang, B., Koomen, J. M., Mahajan, N. P. H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. Nat Struct Mol Biol, 2012, 19: 930-937, doi:10.1038/nsmb.2356
-
(2012)
Nat Struct Mol Biol
, vol.19
, pp. 930-937
-
-
Mahajan, K.1
Fang, B.2
Koomen, J.M.3
Mahajan, N.P.4
-
186
-
-
33751508862
-
Tyrosine phosphorylation controls PCNA function through protein stability
-
Wang, S. C., Nakajima, Y., Yu, Y. L., Xia, W., Chen, C. T., Yang, C. C., et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol, 2006, 8: 1359-1368, doi:10.1038/ncb1501
-
(2006)
Nat Cell Biol
, vol.8
, pp. 1359-1368
-
-
Wang, S.C.1
Nakajima, Y.2
Yu, Y.L.3
Xia, W.4
Chen, C.T.5
Yang, C.C.6
-
187
-
-
77958022249
-
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus
-
Huo, L., Wang, Y. N., Xia, W., Hsu, S. C., Lai, C. C., Li, L. Y., et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci U S A, 2010, 107: 16125-16130, doi:10.1073/pnas.1000743107
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 16125-16130
-
-
Huo, L.1
Wang, Y.N.2
Xia, W.3
Hsu, S.C.4
Lai, C.C.5
Li, L.Y.6
-
188
-
-
84866128097
-
Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776
-
Yu, Y. L., Chou, R. H., Wu, C. H., Wang, Y. N., Chang, W. J., Tseng, Y. J., et al. Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. J Biol Chem, 2012, 287: 31015-31026, doi:10.1074/jbc.M112.358077
-
(2012)
J Biol Chem
, vol.287
, pp. 31015-31026
-
-
Yu, Y.L.1
Chou, R.H.2
Wu, C.H.3
Wang, Y.N.4
Chang, W.J.5
Tseng, Y.J.6
-
189
-
-
78751558423
-
Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth
-
Zhao, H., Lo, Y. H., Ma, L., Waltz, S. E., Gray, J. K., Hung, M. C., et al. Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol Cancer Ther, 2011, 10: 29-36, doi:10.1158/1535-7163.MCT-10-0778
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 29-36
-
-
Zhao, H.1
Lo, Y.H.2
Ma, L.3
Waltz, S.E.4
Gray, J.K.5
Hung, M.C.6
-
190
-
-
84875973325
-
Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides
-
Yu, Y. L., Chou, R. H., Liang, J. H., Chang, W. J., Su, K. J., Tseng, Y. J., et al. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides. PLoS One, 2013, 8: e61362, doi:10.1371/journal.pone.0061362
-
(2013)
PLoS One
, vol.8
, pp. e61362
-
-
Yu, Y.L.1
Chou, R.H.2
Liang, J.H.3
Chang, W.J.4
Su, K.J.5
Tseng, Y.J.6
-
191
-
-
84897067023
-
Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins
-
Reyes, D., Ballare, C., Castellano, G., Soronellas, D., Bago, J. R., Blanco, J., et al. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins. Oncogene, 2014, 33: 1570-1580, doi:10.1038/onc.2013.95
-
(2014)
Oncogene
, vol.33
, pp. 1570-1580
-
-
Reyes, D.1
Ballare, C.2
Castellano, G.3
Soronellas, D.4
Bago, J.R.5
Blanco, J.6
-
192
-
-
85019203234
-
Mitogen- and stress-activated Kinase 1 mediates Epstein-Barr virus latent membrane protein 1-promoted cell transformation in nasopharyngeal carcinoma through its induction of Fra-1 and c-Jun genes
-
Li, B., Wan, Z., Huang, G., Huang, Z., Zhang, X., Liao, D., et al. Mitogen- and stress-activated Kinase 1 mediates Epstein-Barr virus latent membrane protein 1-promoted cell transformation in nasopharyngeal carcinoma through its induction of Fra-1 and c-Jun genes. BMC Cancer, 2015, 15: 390, doi:10.1186/s12885-015-1398-3
-
(2015)
BMC Cancer
, vol.15
, pp. 390
-
-
Li, B.1
Wan, Z.2
Huang, G.3
Huang, Z.4
Zhang, X.5
Liao, D.6
-
193
-
-
84055223557
-
Characterization of the cellular action of the MSK inhibitor SB-747651A
-
Naqvi, S., Macdonald, A., McCoy, C. E., Darragh, J., Reith, A. D., Arthur, J. S. Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochem J, 2012, 441: 347-357, doi:10.1042/BJ20110970
-
(2012)
Biochem J
, vol.441
, pp. 347-357
-
-
Naqvi, S.1
Macdonald, A.2
McCoy, C.E.3
Darragh, J.4
Reith, A.D.5
Arthur, J.S.6
-
194
-
-
84899048636
-
Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma
-
Johnson, J., Shi, Z., Liu, Y., Stack, M. S. Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma. Oral Oncol, 2014, 50: 468-477, doi:10.1016/j.oraloncology.2014.02.004
-
(2014)
Oral Oncol
, vol.50
, pp. 468-477
-
-
Johnson, J.1
Shi, Z.2
Liu, Y.3
Stack, M.S.4
-
195
-
-
38349053791
-
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
-
Pardanani, A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia, 2008, 22: 23-30, doi:10.1038/sj.leu.2404948
-
(2008)
Leukemia
, vol.22
, pp. 23-30
-
-
Pardanani, A.1
-
196
-
-
84937395764
-
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
-
Wu, S. C., Li, L. S., Kopp, N., Montero, J., Chapuy, B., Yoda, A., et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28: 29-41, doi:10.1016/j.ccell.2015.06.005
-
(2015)
Cancer Cell
, vol.28
, pp. 29-41
-
-
Wu, S.C.1
Li, L.S.2
Kopp, N.3
Montero, J.4
Chapuy, B.5
Yoda, A.6
-
197
-
-
84945218784
-
WEE1 Kinase As a Target for Cancer Therapy
-
Mueller, S., Haas-Kogan, D. A. WEE1 Kinase As a Target for Cancer Therapy. J Clin Oncol, 2015, doi:10.1200/JCO.2015.62.2290
-
J Clin Oncol
, pp. 2015
-
-
Mueller, S.1
Haas-Kogan, D.A.2
-
198
-
-
0036202004
-
Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor
-
Li, J., Wang, Y., Sun, Y., Lawrence, T. S. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res, 2002, 157: 322-330
-
(2002)
Radiat Res
, vol.157
, pp. 322-330
-
-
Li, J.1
Wang, Y.2
Sun, Y.3
Lawrence, T.S.4
-
199
-
-
33846608696
-
Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line
-
Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer, 2006, 6: 292, doi:10.1186/1471-2407-6-292
-
(2006)
BMC Cancer
, vol.6
, pp. 292
-
-
Hashimoto, O.1
Shinkawa, M.2
Torimura, T.3
Nakamura, T.4
Selvendiran, K.5
Sakamoto, M.6
-
200
-
-
77953711939
-
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
-
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther, 2010, 9: 514-522
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 514-522
-
-
Hirai, H.1
Arai, T.2
Okada, M.3
Nishibata, T.4
Kobayashi, M.5
Sakai, N.6
-
201
-
-
80052491760
-
MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
-
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res, 2011, 17: 5638-5648, doi:10.1158/1078-0432.CCR-11-0650
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5638-5648
-
-
Bridges, K.A.1
Hirai, H.2
Buser, C.A.3
Brooks, C.4
Liu, H.5
Buchholz, T.A.6
-
202
-
-
79955492036
-
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts
-
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res, 2011, 17: 2799-2806, doi:10.1158/1078-0432.CCR-10-2580
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2799-2806
-
-
Rajeshkumar, N.V.1
De Oliveira, E.2
Ottenhof, N.3
Watters, J.4
Brooks, D.5
Demuth, T.6
-
203
-
-
84855645086
-
MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells
-
Kreahling, J. M., Gemmer, J. Y., Reed, D., Letson, D., Bui, M., Altiok, S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther, 2012, 11: 174-182, doi:10.1158/1535-7163.MCT-11-0529
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 174-182
-
-
Kreahling, J.M.1
Gemmer, J.Y.2
Reed, D.3
Letson, D.4
Bui, M.5
Altiok, S.6
-
204
-
-
84882253419
-
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
-
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther, 2013, 12: 1442-1452, doi:10.1158/1535-7163.MCT-13-0025
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1442-1452
-
-
Guertin, A.D.1
Li, J.2
Liu, Y.3
Hurd, M.S.4
Schuller, A.G.5
Long, B.6
-
205
-
-
84929279071
-
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
-
Qi, W., Xie, C., Li, C., Caldwell, J. T., Edwards, H., Taub, J. W., et al. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol, 2014, 7: 53, doi:10.1186/s13045-014-0053-9
-
(2014)
J Hematol Oncol
, vol.7
, pp. 53
-
-
Qi, W.1
Xie, C.2
Li, C.3
Caldwell, J.T.4
Edwards, H.5
Taub, J.W.6
-
206
-
-
84945181744
-
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
-
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., et al. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol, 2015, doi:10.1200/JCO.2014.60.4009
-
J Clin Oncol
, pp. 2015
-
-
Do, K.1
Wilsker, D.2
Ji, J.3
Zlott, J.4
Freshwater, T.5
Kinders, R.J.6
-
207
-
-
84927639824
-
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma
-
Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Jr., Mueller, D., Bakken, K. K., et al. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res, 2015, 21: 1916-1924, doi:10.1158/1078-0432.CCR-14-2588
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1916-1924
-
-
Pokorny, J.L.1
Calligaris, D.2
Gupta, S.K.3
Iyekegbe, D.O.4
Mueller, D.5
Bakken, K.K.6
-
208
-
-
84927618199
-
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
-
Zhou, L., Zhang, Y., Chen, S., Kmieciak, M., Leng, Y., Lin, H., et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia, 2015, 29: 807-818, doi:10.1038/leu.2014.296
-
(2015)
Leukemia
, vol.29
, pp. 807-818
-
-
Zhou, L.1
Zhang, Y.2
Chen, S.3
Kmieciak, M.4
Leng, Y.5
Lin, H.6
-
209
-
-
84880941947
-
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O
-
Chen, B., Duan, L., Yin, G., Tan, J., Jiang, X. miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother, 2013, 25: 229-238, doi:10.1179/1973947813Y.0000000092
-
(2013)
J Chemother
, vol.25
, pp. 229-238
-
-
Chen, B.1
Duan, L.2
Yin, G.3
Tan, J.4
Jiang, X.5
-
210
-
-
10044232731
-
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
-
Nielsen, J. S., Jakobsen, E., Holund, B., Bertelsen, K., Jakobsen, A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer, 2004, 14: 1086-1096, doi:10.1111/j.1048-891X.2004.14606.x
-
(2004)
Int J Gynecol Cancer
, vol.14
, pp. 1086-1096
-
-
Nielsen, J.S.1
Jakobsen, E.2
Holund, B.3
Bertelsen, K.4
Jakobsen, A.5
-
211
-
-
34249325876
-
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior
-
Dimri, M., Naramura, M., Duan, L., Chen, J., Ortega-Cava, C., Chen, G., et al. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res, 2007, 67: 4164-4172, doi:10.1158/0008-5472.CAN-06-2580
-
(2007)
Cancer Res
, vol.67
, pp. 4164-4172
-
-
Dimri, M.1
Naramura, M.2
Duan, L.3
Chen, J.4
Ortega-Cava, C.5
Chen, G.6
-
212
-
-
35348848403
-
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
-
Nieto, Y., Nawaz, F., Jones, R. B., Shpall, E. J., Nawaz, S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol, 2007, 25: 4405-4413, doi:10.1200/JCO.2006.09.8822
-
(2007)
J Clin Oncol
, vol.25
, pp. 4405-4413
-
-
Nieto, Y.1
Nawaz, F.2
Jones, R.B.3
Shpall, E.J.4
Nawaz, S.5
-
213
-
-
80053643861
-
Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations
-
Kong, J. H., Park, Y. H., Kim, J. A., Kim, J. H., Yun, J., Sun, J. M., et al. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. Oncology, 2011, 81: 55-62, doi:10.1159/000331417
-
(2011)
Oncology
, vol.81
, pp. 55-62
-
-
Kong, J.H.1
Park, Y.H.2
Kim, J.A.3
Kim, J.H.4
Yun, J.5
Sun, J.M.6
-
214
-
-
84860511478
-
EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia
-
Kallel, I., Khabir, A., Boujelbene, N., Abdennadher, R., Daoud, J., Frikha, M., et al. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. J Recept Signal Transduct Res, 2012, 32: 142-149, doi:10.3109/10799893.2012.664552
-
(2012)
J Recept Signal Transduct Res
, vol.32
, pp. 142-149
-
-
Kallel, I.1
Khabir, A.2
Boujelbene, N.3
Abdennadher, R.4
Daoud, J.5
Frikha, M.6
-
215
-
-
84877683942
-
Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
-
Tang, Y., Zhu, L., Li, Y., Ji, J., Li, J., Yuan, F., et al. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med, 2012, 10 Suppl 1:S4, doi:10.1186/1479-5876-10-S1-S4
-
(2012)
J Transl Med
, pp. S4
-
-
Tang, Y.1
Zhu, L.2
Li, Y.3
Ji, J.4
Li, J.5
Yuan, F.6
-
216
-
-
38949101107
-
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification
-
Angulo, B., Suarez-Gauthier, A., Lopez-Rios, F., Medina, P. P., Conde, E., Tang, M., et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol, 2008, 214: 347-356, doi:10.1002/path.2267
-
(2008)
J Pathol
, vol.214
, pp. 347-356
-
-
Angulo, B.1
Suarez-Gauthier, A.2
Lopez-Rios, F.3
Medina, P.P.4
Conde, E.5
Tang, M.6
-
217
-
-
68949213744
-
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
-
Hirsch, F. R., Varella-Garcia, M., Cappuzzo, F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 2009, 28 Suppl 1:S32-37, doi:10.1038/onc.2009.199
-
(2009)
Oncogene
, vol.28
, pp. S32-S37
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Cappuzzo, F.3
-
218
-
-
77349083210
-
Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer
-
Chen, C. C., Chiu, H. H., Yen, L. C., Chang, H. J., Chang, M. S., Tsai, J. R., et al. Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. Oncol Rep, 2010, 23: 639-645
-
(2010)
Oncol Rep
, vol.23
, pp. 639-645
-
-
Chen, C.C.1
Chiu, H.H.2
Yen, L.C.3
Chang, H.J.4
Chang, M.S.5
Tsai, J.R.6
-
219
-
-
84905378090
-
EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival
-
Sabattini, S., Mancini, F. R., Marconato, L., Bacci, B., Rossi, F., Vignoli, M., et al. EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. Vet Comp Oncol, 2014, 12: 237-248, doi:10.1111/vco.12002
-
(2014)
Vet Comp Oncol
, vol.12
, pp. 237-248
-
-
Sabattini, S.1
Mancini, F.R.2
Marconato, L.3
Bacci, B.4
Rossi, F.5
Vignoli, M.6
-
220
-
-
84655170171
-
Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis
-
Guo, G. F., Cai, Y. C., Zhang, B., Xu, R. H., Qiu, H. J., Xia, L. P., et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol, 2011, 28 Suppl 1:S197-203, doi:10.1007/s12032-010-9696-8
-
(2011)
Med Oncol
, vol.28
, pp. S197-S203
-
-
Guo, G.F.1
Cai, Y.C.2
Zhang, B.3
Xu, R.H.4
Qiu, H.J.5
Xia, L.P.6
-
221
-
-
0038545803
-
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase
-
Bulgaru, A. M., Mani, S., Goel, S., Perez-Soler, R. Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther, 2003, 3: 269-279, doi:10.1586/14737140.3.3.269
-
(2003)
Expert Rev Anticancer Ther
, vol.3
, pp. 269-279
-
-
Bulgaru, A.M.1
Mani, S.2
Goel, S.3
Perez-Soler, R.4
-
222
-
-
0346991841
-
EGFR tyrosine kinase inhibitor «gefitinib (Iressa)» for cancer therapy
-
Yano, S., Yamaguchi, M., Dong, R. P. EGFR tyrosine kinase inhibitor «gefitinib (Iressa)» for cancer therapy. Nihon Yakurigaku Zasshi, 2003, 122: 491-497
-
(2003)
Nihon Yakurigaku Zasshi
, vol.122
, pp. 491-497
-
-
Yano, S.1
Yamaguchi, M.2
Dong, R.P.3
-
223
-
-
10444267243
-
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours
-
Ng, M., Cunningham, D. Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract, 2004, 58: 970-976
-
(2004)
Int J Clin Pract
, vol.58
, pp. 970-976
-
-
Ng, M.1
Cunningham, D.2
-
224
-
-
33747146789
-
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer
-
Johnston, S. R., Leary, A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc), 2006, 42: 441-453, doi:10.1358/dot.2006.42.7.985637
-
(2006)
Drugs Today (Barc)
, vol.42
, pp. 441-453
-
-
Johnston, S.R.1
Leary, A.2
-
225
-
-
84887326965
-
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
-
Chen, Y. J., Yeh, M. H., Yu, M. C., Wei, Y. L., Chen, W. S., Chen, J. Y., et al. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res, 2013, 15: R108, doi:10.1186/bcr3575
-
(2013)
Breast Cancer Res
, vol.15
, pp. R108
-
-
Chen, Y.J.1
Yeh, M.H.2
Yu, M.C.3
Wei, Y.L.4
Chen, W.S.5
Chen, J.Y.6
-
226
-
-
84875408831
-
Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells
-
Hsia, T. C., Tu, C. Y., Chen, Y. J., Wei, Y. L., Yu, M. C., Hsu, S. C., et al. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Mol Pharmacol, 2013, 83: 857-869, doi:10.1124/mol.112.082743
-
(2013)
Mol Pharmacol
, vol.83
, pp. 857-869
-
-
Hsia, T.C.1
Tu, C.Y.2
Chen, Y.J.3
Wei, Y.L.4
Yu, M.C.5
Hsu, S.C.6
-
227
-
-
33845674883
-
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
-
Cohenuram, M., Saif, M. W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs, 2007, 18: 7-15, doi:10.1097/CAD.0b013e32800feecb
-
(2007)
Anticancer Drugs
, vol.18
, pp. 7-15
-
-
Cohenuram, M.1
Saif, M.W.2
-
228
-
-
84962205018
-
ASPP and iASPP: Implication in cancer development and progression
-
Li, Y., Ahmad, A., Sarkar and F. H., ASPP and iASPP: Implication in cancer development and progression. Cell. Mol. Biol. 2015, 61(6): 2-8.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 2-8
-
-
Li, Y.1
Ahmad, A.2
Sarkar, F.H.3
-
229
-
-
84962175330
-
Association of NOTCH with different microRNAs in head and neck cancer
-
Masood, N., Qureshi, M. Z. and Yasmin, A., Association of NOTCH with different microRNAs in head and neck cancer. Cell. Mol. Biol. 2015, 61(6): 9-16.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 9-16
-
-
Masood, N.1
Qureshi, M.Z.2
Yasmin, A.3
-
230
-
-
84962147369
-
The role of microRNAs in the resistance to colorectal cancer treatments
-
Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolken hauerand, O. and Schmitz, U., The role of microRNAs in the resistance to colorectal cancer treatments. Cell. Mol. Biol. 2015, 61(6): 17-23.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 17-23
-
-
Amirkhah, R.1
Farazmand, A.2
Irfan-Maqsood, M.3
Wolken Hauerand, O.4
Schmitz, U.5
-
231
-
-
84962167853
-
The Notch signaling pathway in esophageal adenocarcinoma
-
Wang, Z., Chen, J. and Capobianco, A. J., The Notch signaling pathway in esophageal adenocarcinoma. Cell. Mol. Biol. 2015, 61(6): 24-32.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 24-32
-
-
Wang, Z.1
Chen, J.2
Capobianco, A.J.3
-
232
-
-
84962191062
-
TRAIL and targeting cancer cells: between promises and obstacles
-
Limami, Y., Pinon, A., Riaz, A. and Simon, A., TRAIL and targeting cancer cells: between promises and obstacles. Cell. Mol. Biol. 2015, 61(6): 33-38.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 33-38
-
-
Limami, Y.1
Pinon, A.2
Riaz, A.3
Simon, A.4
-
233
-
-
84962184047
-
Cancer stem cells in head and neck cancer: A Mini Review
-
Silva Galbiatti-Dias, A. L., Pavarino, É. C., Kawasaki-Oyama, R. S., Maniglia, J. V., Maniglia, E. J. V. and Goloni Bertollo, E. M., Cancer stem cells in head and neck cancer: A Mini Review. Cell. Mol. Biol. 2015, 61(6): 39-43.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 39-43
-
-
Silva Galbiatti-Dias, A.L.1
Pavarino, E.C.2
Kawasaki-Oyama, R.S.3
Maniglia, J.V.4
Maniglia, E.J.V.5
Goloni Bertollo, E.M.6
-
234
-
-
84962173003
-
PARP inhibition: A promising therapeutic target in ovarian cancer
-
Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Casorelli, A., Domenici, L., Imperiale, L., Ruscito, I., Abdul Halim, T., Palaia, I., Di Donato, V., Pecorini, F., Monti, M., Muzii, L. and Panici, P. B., PARP inhibition: A promising therapeutic target in ovarian cancer. Cell. Mol. Biol. 2015, 61(6): 44-61.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 44-61
-
-
Musella, A.1
Marchetti, C.2
Gasparri, M.L.3
Salerno, L.4
Casorelli, A.5
Domenici, L.6
Imperiale, L.7
Ruscito, I.8
Abdul Halim, T.9
Palaia, I.10
Di Donato, V.11
Pecorini, F.12
Monti, M.13
Muzii, L.14
Panici, P.B.15
-
235
-
-
84962173208
-
Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites
-
Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M. S., Nogueira, D. R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A. A. and Ismail, M., Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell. Mol. Biol. 2015, 61(6): 62-68.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 62-68
-
-
Attar, R.1
Tabassum, S.2
Fayyaz, S.3
Ahmad, M.S.4
Nogueira, D.R.5
Yaylim, I.6
Timirci-Kahraman, O.7
Kucukhuseyin, O.8
Cacina, C.9
Farooqi, A.A.10
Ismail, M.11
-
236
-
-
84962171220
-
Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells
-
Chong, L-W., Chou, R-H., Liao, C-C., Lee, T-F., Lin, Y., Yang, K-C. and Hsu, Y-C. Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells. Cell. Mol. Biol. 2015, 61(6): 85-91.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 85-91
-
-
Chong, L.-W.1
Chou, R.-H.2
Liao, C.-C.3
Lee, T.-F.4
Lin, Y.5
Yang, K.-C.6
Hsu, Y.-C.7
-
237
-
-
84962141567
-
Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins
-
Smina, T. P., Mohan, A., Ayyappa, K. A., Sethuraman, S. and Krishnan, U. M., Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins. Cell. Mol. Biol. 2015, 61(6): 92-99.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 92-99
-
-
Smina, T.P.1
Mohan, A.2
Ayyappa, K.A.3
Sethuraman, S.4
Krishnan, U.M.5
-
238
-
-
84962168850
-
Indirect role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach
-
Ahmadi, M., Jafari, R., Marashi, S. A. and Farazmand, A., Indirect role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach. Cell. Mol. Biol. 2015, 61(6): 100-107.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 100-107
-
-
Ahmadi, M.1
Jafari, R.2
Marashi, S.A.3
Farazmand, A.4
-
239
-
-
84962165962
-
Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population
-
Zahoor, A., Mansoor, Q., Farooqi, A. A., Fayyaz, S., Naz, G. and Ismail, M., Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population. Cell. Mol. Biol. 2015, 61(6): 108-112.
-
(2015)
Cell. Mol. Biol.
, vol.61
, Issue.6
, pp. 108-112
-
-
Zahoor, A.1
Mansoor, Q.2
Farooqi, A.A.3
Fayyaz, S.4
Naz, G.5
Ismail, M.6
|